Player FM - Internet Radio Done Right
Checked 7d ago
Added four years ago
Content provided by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Podcasts Worth a Listen
SPONSORED
<
<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/we-have-the-receipts">We Have The Receipts</a></span>


Hosted by Chris Burns, We Have The Receipts is a bi-weekly all-access deep dive into Netflix Unscripted Reality! Each episode will bring you closer to the people behind the reality, with the free-flowing depth of podcast conversations and viral elements of TV’s best talk shows. We Have The Receipts is an upbeat, fan-first destination to uncover more insider secrets, more expert hot takes, and more off-the-rails drama from their favorite Netflix reality stars.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Mark all (un)played …
Manage series 2942795
Content provided by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
…
continue reading
303 episodes
Mark all (un)played …
Manage series 2942795
Content provided by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
…
continue reading
303 episodes
Tutti gli episodi
×P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sharon Cohen, MD, FRCPC, Scott A. Kaiser, MD - AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions in Primary Care 36:25
36:25
Play Later
Play Later
Lists
Like
Liked36:25
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SUC865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 18, 2026. AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions in Primary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Christine Franzese, MD, FARS - Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider’s Role in Patient Care 56:44
56:44
Play Later
Play Later
Lists
Like
Liked56:44
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026. Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider’s Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sara M. Tinsley-Vance, PhD, APRN, AOCN - Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics 1:28:12
1:28:12
Play Later
Play Later
Lists
Like
Liked1:28:12
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026. Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by independent medical education grants from GSK and Incyte Corporation. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan S. Appelbaum, MD, FACP, AAHIVS - Defining and Delivering Person-Centric HIV Care in Key Populations 46:41
46:41
Play Later
Play Later
Lists
Like
Liked46:41
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JJX865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until April 27, 2026. Defining and Delivering Person-Centric HIV Care in Key Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Gilead Sciences, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Brenda L. Tesini, MD, Charles Vega, MD, FAAFP - Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance 1:03:36
1:03:36
Play Later
Play Later
Lists
Like
Liked1:03:36
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DEN865. CME/AAPA credit will be available until April 24, 2026. Primary Care at the Center of RSV Prevention: Community-Focused Strategies to Foster Trust and Vaccine Acceptance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by an independent medical education grant from GSK. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Milind Desai, MD, MBA, FACC, FAHA, FESC / Anjali Tiku Owens, MD - Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data 50:54
50:54
Play Later
Play Later
Lists
Like
Liked50:54
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026. Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Bristol Myers Squibb. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Colleen F. Kelley, MD, MPH - Progressing PrEP: Latest PrEP Advances to Prevent HIV Transmissions 43:03
43:03
Play Later
Play Later
Lists
Like
Liked43:03
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/CECH/IPCE information, and to apply for credit, please visit us at PeerView.com/NQE865. CME/MOC/NCPD/CPE/AAPA/CECH/IPCE credit will be available until April 20, 2026. Progressing PrEP: Latest PrEP Advances to Prevent HIV Transmissions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This program has been supported by an independent educational grant from Gilead Sciences, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Melanie Davies - Seeing Beyond the Numbers in Type 2 Diabetes: Empowering Patients for Optimal Weight and Glycaemic Management 59:29
59:29
Play Later
Play Later
Lists
Like
Liked59:29
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MJX865. CME credit will be available until 8 May 2026. Seeing Beyond the Numbers in Type 2 Diabetes: Empowering Patients for Optimal Weight and Glycaemic Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Prof. Nick Fox - Exploring the Promise of Biomarkers and ATTs in Diagnosing and Treating Early Symptomatic Alzheimer's Disease: Key Takeaways From AD/PD 2025 and AAN 2025 32:42
32:42
Play Later
Play Later
Lists
Like
Liked32:42
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/BRK865. CME/MOC/NCPD/AAPA credit will be available until April 29, 2026. Exploring the Promise of Biomarkers and ATTs in Diagnosing and Treating Early Symptomatic Alzheimer’s Disease: Key Takeaways From AD/PD 2025 and AAN 2025 In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs 1:04:16
1:04:16
Play Later
Play Later
Lists
Like
Liked1:04:16
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026. A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women’s Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anna Chodos, MD, MPH - Brain Health Essentials: Strategies for Adapting Clinical Practice and Workflows to Optimize Cognitive Functioning in an Aging Population 1:00:37
1:00:37
Play Later
Play Later
Lists
Like
Liked1:00:37
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/BGW865. CME/MOC/NCPD/IPCE credit will be available until April 4, 2026. Brain Health Essentials: Strategies for Adapting Clinical Practice and Workflows to Optimize Cognitive Functioning in an Aging Population In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Haydar Frangoul, MD, MS, Julie Kanter, MD - Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT 57:32
57:32
Play Later
Play Later
Lists
Like
Liked57:32
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/YKX865. CME/NCPD credit will be available until April 18, 2026. Innovation Takes Shape in SCD: Rewriting Management Principles With Gene Therapy and Revisiting the Role of HCT In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Vertex Pharmaceuticals. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Carel le Roux, MBChB, FRCP, FRCPath, PhD / Donna H. Ryan, MD, FTOS - Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease 1:02:40
1:02:40
Play Later
Play Later
Lists
Like
Liked1:02:40
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026. Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sophia A. Patel, MD - Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs 26:16
26:16
Play Later
Play Later
Lists
Like
Liked26:16
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KVY865. CME/MOC/AAPA credit will be available until March 19, 2026. Mastering the Art of Referring Pediatric Patients With Eosinophilic Esophagitis to Specialty Care for Timely Treatment: Spotting the Signs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anna Kovalszki, MD, FAAAAI, Michael E. Wechsler, MD - Stories Behind the Science in EGPA: Updated Strategies for Diagnosis, Treatment, and Reducing the Steroid Burden in Patients 1:00:59
1:00:59
Play Later
Play Later
Lists
Like
Liked1:00:59
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AHR865. CME/MOC/AAPA credit will be available until March 27, 2026. Stories Behind the Science in EGPA: Updated Strategies for Diagnosis, Treatment, and Reducing the Steroid Burden in Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent educational grant from AstraZeneca LP. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Eleonora Lad, MD, PhD - Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? 47:12
47:12
Play Later
Play Later
Lists
Like
Liked47:12
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026. Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 MeiLan K. Han, MD, MS - Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis 32:50
32:50
Play Later
Play Later
Lists
Like
Liked32:50
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTR865. CME/MOC/AAPA credit will be available until March 10, 2026. Expert Insights on the Use of Targeted Biologic Therapy in Patients With COPD and Evidence of Type 2 Inflammation: Taking It on a Case-by-Case Basis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Maissaa Janbain, MD, MSCR - Leveling the Standard of Care in Hemophilia A: Insights and Strategies for Developing Effective, Personalized Treatment Plans 50:53
50:53
Play Later
Play Later
Lists
Like
Liked50:53
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026. Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Angela Fitch, MD, FACP, FOMA - Breaking Through Biases in Obesity Management: Building Competence, Creating Connections, and Empowering Leaders in Primary Care 1:05:15
1:05:15
Play Later
Play Later
Lists
Like
Liked1:05:15
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/ZCB865. CME/NCPD/AAPA credit will be available until March 10, 2026. Breaking Through Biases in Obesity Management: Building Competence, Creating Connections, and Empowering Leaders in Primary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 David Bernstein, MD, MACG, FAASLD, AGAF, FACP - Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care 45:57
45:57
Play Later
Play Later
Lists
Like
Liked45:57
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026. Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Erik Musiek, MD, PhD - Visualizing the Role of Neuroinflammation in the Pathophysiology and Management of Alzheimer’s Disease 28:48
28:48
Play Later
Play Later
Lists
Like
Liked28:48
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at PeerView.com/AFJ865. CME credit will be available until March 9, 2026. Visualizing the Role of Neuroinflammation in the Pathophysiology and Management of Alzheimer’s Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 William Kitchens, MD, PhD, FACS, FAST - Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies 50:08
50:08
Play Later
Play Later
Lists
Like
Liked50:08
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026. Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an educational grant from Bristol Myers Squibb. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 R. Scott Turner, MD, PhD / Charles Vega, MD, FAAFP - Diagnose Early, Communicate Clearly: Optimizing Alzheimer’s Outcomes in Primary Care 35:47
35:47
Play Later
Play Later
Lists
Like
Liked35:47
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DPF865. CME credit will be available until February 19, 2026. Diagnose Early, Communicate Clearly: Optimizing Alzheimer’s Outcomes in Primary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant by Eisai Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Peter Schmid, FRCP, MD, PhD - Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer 55:11
55:11
Play Later
Play Later
Lists
Like
Liked55:11
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026. Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lucia M. Novak, MSN, ANP-BC, BC-ADM - Individualizing Management Plans for Type 2 Diabetes Through Shared Decision-Making: An Office Hours Activity 33:07
33:07
Play Later
Play Later
Lists
Like
Liked33:07
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/UTJ865. CME/NCPD/AAPA credit will be available until February 28, 2026. Individualizing Management Plans for Type 2 Diabetes Through Shared Decision-Making: An Office Hours Activity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Melanie Davies - Understanding the Individual in Front of You: The Importance of Patient Participation in Weight and Glycaemic Management for People With Type 2 Diabetes 35:36
35:36
Play Later
Play Later
Lists
Like
Liked35:36
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EYG865. CME credit will be available until January 23, 2026. Understanding the Individual in Front of You: The Importance of Patient Participation in Weight and Glycaemic Management for People With Type 2 Diabetes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Vera Bril, BSc, FRCPC, MD - Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient 33:12
33:12
Play Later
Play Later
Lists
Like
Liked33:12
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026. Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies). Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Amy J. McMichael, MD - From Roots to Results: Elevating Alopecia Areata Management 39:24
39:24
Play Later
Play Later
Lists
Like
Liked39:24
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QXZ865. CME/NCPD/AAPA/IPCE credit will be available until January 16, 2026. From Roots to Results: Elevating Alopecia Areata Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Pfizer. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Kristina M. Deligiannidis, MD - The Future of Care in Postpartum Depression: Comprehensive Strategies for Early Diagnosis and Effective Treatment 44:05
44:05
Play Later
Play Later
Lists
Like
Liked44:05
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NCN865. CME/MOC/AAPA credit will be available until January 19, 2026. The Future of Care in Postpartum Depression: Comprehensive Strategies for Early Diagnosis and Effective Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sage Therapeutics and Biogen. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Mrinal Gounder, MD - Advancing Therapeutic Control in Desmoid Tumors: Expert Guidance on Modern Diagnostic and Treatment Practices With Gamma Secretase Inhibitors 49:04
49:04
Play Later
Play Later
Lists
Like
Liked49:04
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QXP865. CME/AAPA credit will be available until December 8, 2025. Advancing Therapeutic Control in Desmoid Tumors: Expert Guidance on Modern Diagnostic and Treatment Practices With Gamma Secretase Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Vanita R. Aroda, MD - Intensifying Treatment for Type 2 Diabetes According to Current Guidelines: An Office Hours Activity 28:21
28:21
Play Later
Play Later
Lists
Like
Liked28:21
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NRC865. CME/NCPD/AAPA credit will be available until January 11, 2025. Intensifying Treatment for Type 2 Diabetes According to Current Guidelines: An Office Hours Activity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Nancy S. Reau, MD - Plugging the Gaps in Hepatitis B and C Care: Understanding and Integrating New Guidelines and Advances in Disease Management 1:08:10
1:08:10
Play Later
Play Later
Lists
Like
Liked1:08:10
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/EWQ865. CME/MOC/NCPD/AAPA credit will be available until December 17, 2025. Plugging the Gaps in Hepatitis B and C Care: Understanding and Integrating New Guidelines and Advances in Disease Management In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hepatitis B Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This program has been supported by an independent educational grant from Gilead Sciences, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Aaron B. Waxman, MD, PhD - Managing Pulmonary Arterial Hypertension in the Era of Novel and Emerging Treatment Options: It Takes a Village 49:12
49:12
Play Later
Play Later
Lists
Like
Liked49:12
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MVM865. CME/AAPA/IPCE credit will be available until December 22, 2025. Managing Pulmonary Arterial Hypertension in the Era of Novel and Emerging Treatment Options: It Takes a Village In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Ira M. Jacobson, MD - In Pursuit of a Functional Cure for Hepatitis B: Monitoring Effectively, Optimizing Treatment, and Reducing Risk of Complications 1:21:25
1:21:25
Play Later
Play Later
Lists
Like
Liked1:21:25
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/STZ865. CME/MOC credit will be available until December 16, 2025. In Pursuit of a Functional Cure for Hepatitis B: Monitoring Effectively, Optimizing Treatment, and Reducing Risk of Complications In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by an independent medical education grant from GSK. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jason J. Luke, MD, FACP - Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? 29:04
29:04
Play Later
Play Later
Lists
Like
Liked29:04
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025. Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Chris A. Liacouras, MD - Optimizing Outcomes for Pediatric Patients With EoE: The Importance of Timely Integration of Targeted Biologic Treatment 1:20:43
1:20:43
Play Later
Play Later
Lists
Like
Liked1:20:43
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DEA865. CME/MOC/AAPA credit will be available until December 7, 2025. Optimizing Outcomes for Pediatric Patients With EoE: The Importance of Timely Integration of Targeted Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Kevin Ault, MD, FIDSA, FACOG - The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis 59:06
59:06
Play Later
Play Later
Lists
Like
Liked59:06
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CJB865. CME credit will be available until November 16, 2025. The Burden of RSV in Pediatric Populations: Evidence for Reshaping Care and Optimizing Prophylaxis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Mirna Chehade, MD, MPH, AGAF, FAAAAI / Evan S. Dellon, MD, MPH - Early Diagnosis and Evolving Management of Eosinophilic Esophagitis in the Era of Targeted Therapy 55:53
55:53
Play Later
Play Later
Lists
Like
Liked55:53
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PUG865. CME/MOC/AAPA/IPCE credit will be available until November 20, 2025. Early Diagnosis and Evolving Management of Eosinophilic Esophagitis in the Era of Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Fuad El Rassi, MD, Modupe Idowu, MD - A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics 1:23:59
1:23:59
Play Later
Play Later
Lists
Like
Liked1:23:59
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/EEY865. CME/AAPA credit will be available until November 24, 2025. A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by independent educational grants from Agios Pharmaceuticals, Inc., and Novo Nordisk Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Irl Hirsch, MD, MACP - The New Normal: Digital Technologies for People Living With Insulin-Treated Type 2 Diabetes 56:26
56:26
Play Later
Play Later
Lists
Like
Liked56:26
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/UHT865. CME/NCPD/AAPA credit will be available until October 31, 2025. The New Normal: Digital Technologies for People Living With Insulin-Treated Type 2 Diabetes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Guillermo E. Umpierrez, MD, CDE, FACP, FACE - Prioritizing Weight Management as a Primary Goal in People With Type 2 Diabetes: An Office Hours Activity 30:47
30:47
Play Later
Play Later
Lists
Like
Liked30:47
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RWC865. CME/NCPD/AAPA credit will be available until November 29, 2025. Prioritizing Weight Management as a Primary Goal in People With Type 2 Diabetes: An Office Hours Activity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 James F. Howard Jr., MD, FAAN / Nicholas J. Silvestri, MD, FAAN - Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm 1:04:03
1:04:03
Play Later
Play Later
Lists
Like
Liked1:04:03
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JDS865. CME credit will be available until November 16, 2025. Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from argenx US, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC - Changing the Future for Families With HoFH: Long-Term Benefits of Early Diagnosis and Treatment for Homozygous Familial Hypercholesterolemia 59:00
59:00
Play Later
Play Later
Lists
Like
Liked59:00
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/MRJ865. CME/MOC/NCPD/CPE/AAPA credit will be available until October 17, 2025. Changing the Future for Families With HoFH: Long-Term Benefits of Early Diagnosis and Treatment for Homozygous Familial Hypercholesterolemia In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Family Heart Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Pamela J. McShane, MD - Experts vs AI Challenge: Diagnosing and Managing Nontuberculous Mycobacterial Lung Disease 56:10
56:10
Play Later
Play Later
Lists
Like
Liked56:10
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPW865. CME/MOC/AAPA/IPCE credit will be available until November 6, 2025. Experts vs AI Challenge: Diagnosing and Managing Nontuberculous Mycobacterial Lung Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Insmed. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 April W. Armstrong, MD, MPH - Staying on Target Against Moderate to Severe Psoriasis: Strategies for Achieving Sustained Benefits Through TYK2 Inhibition 48:16
48:16
Play Later
Play Later
Lists
Like
Liked48:16
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RJG865. CME/MOC/AAPA/IPCE credit will be available until October 22, 2025. Staying on Target Against Moderate to Severe Psoriasis: Strategies for Achieving Sustained Benefits Through TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Bristol Myers Squibb. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Gil Rabinovici, MD - At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies 48:08
48:08
Play Later
Play Later
Lists
Like
Liked48:08
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/GBW865. CME/MOC/NCPD/AAPA credit will be available until October 7, 2025. At the Ready for a New Standard of Alzheimer's Care: Preparing Your Practice for the New Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Matthew C. Breeggemann, MD / John C. Lieske, MD - Stepping Stones on the Path to a Healthier Future for Patients With Primary Hyperoxaluria Type 1: Expert Perspectives on Ensuring Timely Diagnosis… 36:39
36:39
Play Later
Play Later
Lists
Like
Liked36:39
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EZY865. CME credit will be available until October 9, 2025. Stepping Stones on the Path to a Healthier Future for Patients With Primary Hyperoxaluria Type 1: Expert Perspectives on Ensuring Timely Diagnosis and Appropriate Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Onyema Ogbuagu, MD, FACP, FIDSA - Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers 1:07:19
1:07:19
Play Later
Play Later
Lists
Like
Liked1:07:19
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/WHB865. CME/CE/AAPA credit will be available until September 24, 2025. Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity has been supported by an independent educational grant from Gilead Sciences, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer 1:14:57
1:14:57
Play Later
Play Later
Lists
Like
Liked1:14:57
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025. Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Gilead Sciences, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Marc S. Sabatine, MD, MPH - Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care 44:11
44:11
Play Later
Play Later
Lists
Like
Liked44:11
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CXZ865. CME/AAPA credit will be available until September 17, 2025. Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Merck & Co., Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH - Pharmacist-Led RSV Immunization Strategies: Leveraging Trust to Overcome Vaccine Hesitancy 1:00:56
1:00:56
Play Later
Play Later
Lists
Like
Liked1:00:56
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/MFD865. CPE credit will be available until September 20, 2025. Pharmacist-Led RSV Immunization Strategies: Leveraging Trust to Overcome Vaccine Hesitancy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by an independent medical education grant from GSK. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 April W. Armstrong, MD, MPH - All Things Considered in Psoriasis Management: Looking at the Role of Biologic Therapies in a Holistic Approach 1:04:07
1:04:07
Play Later
Play Later
Lists
Like
Liked1:04:07
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GMW865. CME/CE/AAPA/IPCE credit will be available until September 3, 2025. All Things Considered in Psoriasis Management: Looking at the Role of Biologic Therapies in a Holistic Approach In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 John E. Anderson, MD - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal 34:20
34:20
Play Later
Play Later
Lists
Like
Liked34:20
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/USQ865. CME/NCPD/AAPA credit will be available until August 15, 2025. Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Bradley J. Monk, MD, FACS, FACOG - Advancing Immunotherapy: Revolutionizing Cervical Cancer Treatment 35:53
35:53
Play Later
Play Later
Lists
Like
Liked35:53
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YQP865. CME/MOC credit will be available until August 25, 2025. Advancing Immunotherapy: Revolutionizing Cervical Cancer Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Merck & Co., Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Christopher L. Moertel, MD - Mapping a New Treatment Journey in NF1: New Developments With MEKi for Pediatric and Adult Patients With NF1-Plexiform Neurofibromas 37:22
37:22
Play Later
Play Later
Lists
Like
Liked37:22
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DET865. CME/AAPA credit will be available until August 21, 2025. Mapping a New Treatment Journey in NF1: New Developments With MEKi for Pediatric and Adult Patients With NF1-Plexiform Neurofibromas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Stacey B. Trooskin, MD, PhD, Robert G Gish, MD - A Modern Take on Hepatitis Immunization: Overcoming Today's Hurdles With Recent Guidelines and Practical Strategies 1:01:28
1:01:28
Play Later
Play Later
Lists
Like
Liked1:01:28
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SHN865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 14, 2025. A Modern Take on Hepatitis Immunization: Overcoming Today's Hurdles With Recent Guidelines and Practical Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This educational activity is supported by an independent medical education grant from GSK. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 P. Barton Duell, MD - Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies 48:07
48:07
Play Later
Play Later
Lists
Like
Liked48:07
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025. Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs 1:04:40
1:04:40
Play Later
Play Later
Lists
Like
Liked1:04:40
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025. Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jamy D. Ard, MD, FTOS - Breaking Through Biases: Building Skills for Collaborative Weight Management in Primary Care and Treating Obesity as a Chronic Disease 1:06:20
1:06:20
Play Later
Play Later
Lists
Like
Liked1:06:20
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TBR865. CME/NCPD/AAPA credit will be available until July 17, 2025. Breaking Through Biases: Building Skills for Collaborative Weight Management in Primary Care and Treating Obesity as a Chronic Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Maissaa Janbain, MD, MSCR - Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches 30:43
30:43
Play Later
Play Later
Lists
Like
Liked30:43
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025. Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from CSL Behring. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Benjamin M. Greenberg, MD, MHS - Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care 46:09
46:09
Play Later
Play Later
Lists
Like
Liked46:09
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025. Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Genentech, a member of the Roche Group. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP 39:52
39:52
Play Later
Play Later
Lists
Like
Liked39:52
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025. Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jaime Almandoz, MD, MBA, FTOS / Safia Khan, MD - Cases in Practice: Prioritizing Weight Loss for People With Sleep Disorders and Overweight/Obesity 54:17
54:17
Play Later
Play Later
Lists
Like
Liked54:17
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/SRY865. CME/MOC credit will be available until June 20, 2025. Cases in Practice: Prioritizing Weight Loss for People With Sleep Disorders and Overweight/Obesity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Amit Bar-Or, MD, FRCPC / Jiwon Oh, MD, PhD, FRCPC - Taking a Closer Look at Each Patient: Exploring Novel Biomarker and Imaging Strategies in MS 1:01:02
1:01:02
Play Later
Play Later
Lists
Like
Liked1:01:02
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/UCT865. CME/NCPD/CPE/IPCE credit will be available until June 29, 2025. Taking a Closer Look at Each Patient: Exploring Novel Biomarker and Imaging Strategies in MS In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Javier Morales, MD, FACP, FACE - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People with T2DM 22:51
22:51
Play Later
Play Later
Lists
Like
Liked22:51
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/ZKT865. CME/CE/AAPA credit will be available until June 11, 2025. Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People with T2DM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Kun "Kevin" Xiang, MD, PhD - Anticoagulation Therapy in NVAF: A Quality Improvement Initiative 30:17
30:17
Play Later
Play Later
Lists
Like
Liked30:17
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/MXE865. CME/MOC/NCPD/CPE credit will be available until June 12, 2025. Anticoagulation Therapy in NVAF: A Quality Improvement Initiative The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 William Anderson, MD - Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of… 46:53
46:53
Play Later
Play Later
Lists
Like
Liked46:53
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025. Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Brett Elicker, MD / David E. Griffith, MD, ATSF, ACCP, OFRSM - Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation… 54:24
54:24
Play Later
Play Later
Lists
Like
Liked54:24
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VGY865. CME/MOC credit will be available until June 4, 2025. Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Insmed. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM 33:36
33:36
Play Later
Play Later
Lists
Like
Liked33:36
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025. Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Pfizer. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Doreen J. Addrizzo-Harris, MD / Cedric "Jamie" Rutland, MD - Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New… 59:42
59:42
Play Later
Play Later
Lists
Like
Liked59:42
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025. Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Insmed. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Rohit Loomba, MD, MHSc - Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH? 57:31
57:31
Play Later
Play Later
Lists
Like
Liked57:31
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RNX865. CME credit will be available until June 19, 2025. Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Monica Gandhi, MD, MPH - Adapting HIV Treatment for People With Substance Use Disorder 47:30
47:30
Play Later
Play Later
Lists
Like
Liked47:30
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/VCQ865. CME/MOC/CE/AAPA credit will be available until June 4, 2025. Adapting HIV Treatment for People With Substance Use Disorder In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Gilead Sciences, Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sharon Cohen, MD, FRCPC - Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment 1:02:06
1:02:06
Play Later
Play Later
Lists
Like
Liked1:02:06
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQG865. CME/MOC/AAPA credit will be available until May 20, 2025. Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan A. Bernstein, MD - Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic Urticaria 29:54
29:54
Play Later
Play Later
Lists
Like
Liked29:54
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025. Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic Urticaria The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Saakshi Khattri, MBBS, MD, FAAD, FACR - Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors 1:23:17
1:23:17
Play Later
Play Later
Lists
Like
Liked1:23:17
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VEX865. CME/AAPA credit will be available until April 24, 2025. Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Crohn's and Colitis Foundation, National Eczema Association, and Spondylitis Association of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent educational grant from AbbVie. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan A. Bernstein, MD - BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment 39:44
39:44
Play Later
Play Later
Lists
Like
Liked39:44
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025. BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice 1:00:05
1:00:05
Play Later
Play Later
Lists
Like
Liked1:00:05
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025. Biologics in CRSwNP: Putting a Paradigm Shift Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals 47:16
47:16
Play Later
Play Later
Lists
Like
Liked47:16
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025. Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Merck & Co., Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 A. Michael Lincoff, MD - Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy 30:37
30:37
Play Later
Play Later
Lists
Like
Liked30:37
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025. Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Olalekan Oluwole, MBBS, MPH - Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy 1:20:45
1:20:45
Play Later
Play Later
Lists
Like
Liked1:20:45
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/HKJ865. CME/NCPD credit will be available until April 15, 2025. Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Novartis Pharmaceuticals Corporation. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Carlos G. Romo, MD, Aimee Sato, MD - Precision and Progress Against NF1: Solutions for Better Outcomes With MEKi and Multimodal Care for NF1 pNF and Other Tumors 55:14
55:14
Play Later
Play Later
Lists
Like
Liked55:14
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025. Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Alexion Pharmaceuticals. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jennifer Wargo, MD, MMSc - New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy 1:23:33
1:23:33
Play Later
Play Later
Lists
Like
Liked1:23:33
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQH865. CME/MOC/AAPA/IPCE credit will be available until April 21, 2025. New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Richard K. Bogan, MD, FCCP, FAASM - Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment 41:38
41:38
Play Later
Play Later
Lists
Like
Liked41:38
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UVZ865. CME/MOC credit will be available until April 9, 2025. Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Avadel CNS Pharmaceuticals, LLC. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Javier Morales, MD, FACP, FACE - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal 35:33
35:33
Play Later
Play Later
Lists
Like
Liked35:33
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WMV865. CME/NCPD/AAPA credit will be available until March 25, 2025. Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure information is available at the beginning of the video presentation.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Adam Friedman, MD, FAAD - Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis,… 2:17:39
2:17:39
Play Later
Play Later
Lists
Like
Liked2:17:39
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025. Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Adam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi. Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc. Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi. Co-Chair/Planner Shawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi. Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi. Co-Chair/Planner Peter A. Lio, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals. Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme. Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme. Co-Chair/Planner Professor Dedee Murrell has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations 1:06:39
1:06:39
Play Later
Play Later
Lists
Like
Liked1:06:39
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025. A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme. Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited. Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme. Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network. Faculty/Planner Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc. Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Leonard B. Bacharier, MD - Episode 1: Is Your Patient’s Moderate to Severe Asthma Uncontrolled? Global Approaches to Next Steps 14:01
14:01
Play Later
Play Later
Lists
Like
Liked14:01
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Klaus F. Rabe, MD, PhD, FERS - Episode 2: Which Patients Should Receive Targeted Biologic Therapy and When? 20:51
20:51
Play Later
Play Later
Lists
Like
Liked20:51
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Arzu Yorgancioglu, MD - Episode 3: Uncontrolled Moderate to Severe Asthma in Pediatric and Adult Patients Around the World: Comparing Approaches to Treatment Selection 11:48
11:48
Play Later
Play Later
Lists
Like
Liked11:48
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Leonard B. Bacharier, MD - Episode 4: What Are Our Most Significant Challenges in Treating Patients With Moderate to Severe Asthma and What Can We Learn From Each Other? 18:48
18:48
Play Later
Play Later
Lists
Like
Liked18:48
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025. Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated. Speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Other Financial or Material Support for Patents and Royalties from Elsevier. Faculty/Planner Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi. Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi. Presenter Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline. Grant/Research Support from Sanofi. Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Santosh L. Saraf, MD - Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions 25:09
25:09
Play Later
Play Later
Lists
Like
Liked25:09
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QHE865. CME/AAPA credit will be available until February 21, 2025. Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Santosh L. Saraf, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Agios Pharmacueticals, Inc.; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk, Inc.; and Pfizer. Grant/Research Support from Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Alok A. Khorana, MD, FACP, FASCO - REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism 36:00
36:00
Play Later
Play Later
Lists
Like
Liked36:00
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CGE865. CME/MOC/AAPA/IPCE credit will be available until February 28, 2025. REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 R. Scott Wright, MD - Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management 30:04
30:04
Play Later
Play Later
Lists
Like
Liked30:04
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025. Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosures R. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc. CME Reviewer Ramil Goel Assistant Professor of Medicine Division of Cardiovascular Medicine Electrophysiology Section University of Florida College of Medicine Gainesville, Florida Ramil Goel, MD, FHRS, has no relevant financial relationships to disclose.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Joshua B. Wechsler, MD, MSci - Targeting a Brighter Future for Pediatric Patients With Eosinophilic Esophagitis: Ensuring Prompt Diagnosis and Exploring the Role of Biologic Treatment 55:22
55:22
Play Later
Play Later
Lists
Like
Liked55:22
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/DXM865. CME/MOC/AAPA credit will be available until February 12, 2025. Targeting a Brighter Future for Pediatric Patients With Eosinophilic Esophagitis: Ensuring Prompt Diagnosis and Exploring the Role of Biologic Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Campaign Urging Research for Eosinophilic Disease. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Joshua B. Wechsler, MD, MSci, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Ellodi Pharmaceuticals; Regeneron Pharmaceuticals, Inc; and Sanofi. Grant/Research Support from Regeneron Pharmaceuticals, Inc and Sanofi. Speaker for Regeneron Pharmaceuticals, Inc and Sanofi. Patient Advocate/Planner Holly Roland has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anjali Tiku Owens, MD - Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes 1:01:09
1:01:09
Play Later
Play Later
Lists
Like
Liked1:01:09
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025. Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an educational grant from Bristol Myers Squibb. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics. Grant/Research Support from Bristol Myers Squibb. Faculty/Planner Neil Skolnik, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc. Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk. Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Chloe Orkin - Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages 53:54
53:54
Play Later
Play Later
Lists
Like
Liked53:54
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YHX865. CME/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024. Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This program has been supported by an independent educational grant from Gilead Sciences, Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Professor Chloe Orkin has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies. Grant/Research Support from Gilead Sciences, Inc. and ViiV Healthcare group of companies. Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies. Patient Advocate/Planner Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity. Patient Advocate/Planner Donald Young has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and… 50:51
50:51
Play Later
Play Later
Lists
Like
Liked50:51
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024. Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent educational grant from AstraZeneca LP. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Jonathan Corren, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi. Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi. Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi. Co-Chair/Planner Mario Castro, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc. Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma. Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc. Stock Shareholder in Aer Therapeutics. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Shmuel Shoham, MD - Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents 1:30:18
1:30:18
Play Later
Play Later
Lists
Like
Liked1:30:18
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024. Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. Support This activity is supported by an independent educational grant from AstraZeneca LP. Disclosures Shmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc. Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC. Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca and Karius, Inc. Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH). Speaker for International AIDS Society and MDOutlook. Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi. Haleh Simi has no financial interests/relationships or affiliations in relation to this activity. Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships. Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships. All of the relevant financial relationships listed for these individuals have been mitigated.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jorge Plutzky, MD - At the Heart of Obesity: Evidence-Based Strategies for Managing Obesity to Reduce Cardiovascular Risks With Weight Loss Pharmacotherapy 27:07
27:07
Play Later
Play Later
Lists
Like
Liked27:07
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DDA865. CME credit will be available until December 26, 2024. At the Heart of Obesity: Evidence-Based Strategies for Managing Obesity to Reduce Cardiovascular Risks With Weight Loss Pharmacotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Novo Nordisk Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Jorge Plutzky, MD, has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan I. Silverberg, MD, PhD, MPH - Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy 1:05:10
1:05:10
Play Later
Play Later
Lists
Like
Liked1:05:10
Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Stefano Del Prato, MD - Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making 35:26
35:26
Play Later
Play Later
Lists
Like
Liked35:26
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/BVW865. CME/CPD credit will be available until December 27, 2024. Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; Amarin Corporation plc; Applied Therapeutics; EvaPharma; Lilly; The Menarini Group; Novo Nordisk A/S; Sanofi; and Sun Pharmaceutical Industries Ltd. Speaker for Abbott; AstraZeneca; Berlin-Chemie AG; Boehringer Ingelheim International GmbH; Laboratori Guidotti S.p.a.; Lilly; The Menarini Group; Merck Sharp & Dohme; and Novo Nordisk A/S. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic… 55:48
55:48
Play Later
Play Later
Lists
Like
Liked55:48
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025. Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner April W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd. Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc. Co-Chair/Planner Tina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc. Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape 35:22
35:22
Play Later
Play Later
Lists
Like
Liked35:22
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024. Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner PD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. Co-Chair/Planner Jonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi. Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making 23:39
23:39
Play Later
Play Later
Lists
Like
Liked23:39
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EGP865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024. Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an educational grant from Bristol Myers Squibb. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc. Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense. Stock Shareholder in Inspirna, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 W. Troy Donahoo, MD, FTOS - Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change 58:18
58:18
Play Later
Play Later
Lists
Like
Liked58:18
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PZM865. CME/NCPD/AAPA credit will be available until November 26, 2024. Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosures W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity. Amy J. Sheer, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity. Actors of Health Care Theatre have nothing to disclose. Medical Directors Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity. Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care 53:49
53:49
Play Later
Play Later
Lists
Like
Liked53:49
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024. Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Roxana Mehran, MD, has a financial interest/relationship or affiliation in the form of: Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation. Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor). Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC. Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC. Co-Chair/Planner Jeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada. Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Dan Atkins, MD - Facing the Challenges of EoE Head On: A Game Plan for Diagnosis and Integrating Targeted Therapy Using a Team Approach 25:32
25:32
Play Later
Play Later
Lists
Like
Liked25:32
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKS865. CME/MOC/AAPA credit will be available until November 13, 2024. Facing the Challenges of EoE Head On: A Game Plan for Diagnosis and Integrating Targeted Therapy Using a Team Approach In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Dan Atkins, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for The American Partnership for Eosinophilic Disorders (APFED) and CURED. Patient/Planner Valira Pietrangelo has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care 47:21
47:21
Play Later
Play Later
Lists
Like
Liked47:21
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024. Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This program is supported by an independent medical education grant from Jazz Pharmaceuticals. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Josep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG. Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP. Co-Chair/Planner Shubham Pant, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc. Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 James F. Howard Jr., MD - FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application 1:04:29
1:04:29
Play Later
Play Later
Lists
Like
Liked1:04:29
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024. FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from argenx US, Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab. Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc. Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab. Faculty/Planner Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited. Faculty/Planner Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Javier Morales, MD, FACP, FACE / Jay H. Shubrook, DO, FAAFP, FACOFP - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM 58:09
58:09
Play Later
Play Later
Lists
Like
Liked58:09
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/XCX865. CME/AAPA credit will be available until November 26, 2024. Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc. Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc. Co-Chair/Planner Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Javier Morales, MD, FACP, FACE / Jay H. Shubrook, DO, FAAFP, FACOFP - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM 58:20
58:20
Play Later
Play Later
Lists
Like
Liked58:20
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/XCX865. CME/AAPA credit will be available until November 26, 2024. Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc. Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc. Co-Chair/Planner Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Claudia A. Chiriboga, MD, MPH, FAAN - Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood 1:01:32
1:01:32
Play Later
Play Later
Lists
Like
Liked1:01:32
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CRG865. CME/AAPA credit will be available until November 5, 2024. Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Genentech, a member of the Roche Group. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Claudia A. Chiriboga, MD, MPH, FAAN, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis. Grant/Research Support from Biogen; Biohaven, Ltd.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Alan K. Percy, MD - From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management 28:09
28:09
Play Later
Play Later
Lists
Like
Liked28:09
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NQQ865. CME credit will be available until November 9, 2024. From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Alan K. Percy, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Neurogene Inc.; and Taysha Gene Therapies, Inc. Grant/Research Support from Acadia Pharmaceuticals Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Amy S. Paller, MD - Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing… 51:37
51:37
Play Later
Play Later
Lists
Like
Liked51:37
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024. Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment Atopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD. Chair Amy S. Paller, MD Northwestern University Feinberg School of Medicine Chicago, Illinois Patient Advocate Kacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. Disclosure Policy PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education . All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Amy S. Paller, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc. Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc. Patient Advocate/Planner Kacey Jenkins has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice 1:05:01
1:05:01
Play Later
Play Later
Lists
Like
Liked1:05:01
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024. Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an educational grant from Bristol Myers Squibb. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner April W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd. Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc. Faculty/Planner Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc. Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Eric Marsh, MD, PhD - Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management 51:07
51:07
Play Later
Play Later
Lists
Like
Liked51:07
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UDJ865. CME credit will be available until November 20, 2024. Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Eric Marsh, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Acadia Pharmaceuticals Inc. and Stoke Therapeutics. Grant/Research Support from Acadia Pharmaceuticals Inc.; Curaleaf, Inc.; Epygenix Therapeutics, Inc.; Marinus Pharmaceuticals, Inc.; Stoke Therapeutics; and Takeda Pharmaceutical Company Limited. Faculty/Planner David N. Lieberman, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; Neurogene Inc.; and Taysha Gene Therapies, Inc. Grant/Research Support from Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; and Jazz Pharmaceuticals, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 James D. Berry, MD, MPH - Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options 1:00:50
1:00:50
Play Later
Play Later
Lists
Like
Liked1:00:50
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024. Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner James D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen. Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics. Data Safety Monitoring Board for Sanofi. Co-Chair/Planner Sabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation. Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Reynold A. Panettieri, Jr., MD - Expert Perspectives on Improving Early Recognition and Treatment of COPD With Inhalation Therapy 29:42
29:42
Play Later
Play Later
Lists
Like
Liked29:42
To optimally manage patients with chronic obstructive pulmonary disease (COPD), physicians should remain aware of updated guidelines and new evidence on currently available and emerging treatment options. In this activity, a COPD expert reviews the latest diagnostic strategies, classification guidelines, and treatment approaches including dual bronchodilation and triple therapy. Upon completion of this activity, participants should be better able to: Employ evidence-based guidelines to provide a timely and accurate diagnosis of chronic obstructive pulmonary disease (COPD); Create treatment plans for patients with COPD according to evidence-based guidelines, with a goal of optimizing therapy to minimize exacerbation risk, decrease hospitalizations, and mitigate symptoms; and Apply tactics and strategies for shared decision-making to ensure treatment adherence and proper inhaler use.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Hiddo J.L. Heerspink, PhD, PharmD / Prof. Dr. med Christoph Wanner - Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating… 26:48
26:48
Play Later
Play Later
Lists
Like
Liked26:48
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024. Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Hiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc. Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S. Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S. Co-Chair/Planner Prof. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme. Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc. Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Philip J. Mease, MD, MACR - Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care 34:02
34:02
Play Later
Play Later
Lists
Like
Liked34:02
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZQX865. CME credit will be available until November 2, 2024. Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. Support This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Disclosures Philip J. Mease, MD, MACR, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie; ACELYRIN Inc.; Aclaris Therapeutics, Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Galapagos NV; Gilead Sciences, Inc.; GlaxoSmithKline; Inmagene; Janssen Pharmaceuticals, Inc.; Lilly; MoonLake Immunotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Ventyx Biosciences, Inc.; and XinThera. Grant/Research Support from AbbVie.; ACELYRIN Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; and UCB, Inc. Speaker for AbbVie; Amgen; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB, Inc. M.E. Beth Smith, DO, MCR, FACP, has no financial interests/relationships or affiliations in relation to this activity. Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships. Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships. All of the relevant financial relationships listed for these individuals have been mitigated.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for… 57:37
57:37
Play Later
Play Later
Lists
Like
Liked57:37
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865 . NCPD/CE/AAPA credit will be available until November 11, 2024. Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence. Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022. In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn’t watch the live event, this on-demand version is available now! Co-Chair & Moderator Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP The Hamilton Group Behavioral Health LLC Las Vegas, Nevada Co-Chair & Presenter Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE Rasmussen University Bloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Sage Therapeutics and Biogen. Disclosure Policy PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education . All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN). Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN). Co-Chair/Planner Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Point of Care Network (POCN). Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Michael R. Savona, MD / Andrew M. Brunner, MD - Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care 55:45
55:45
Play Later
Play Later
Lists
Like
Liked55:45
Go online to PeerView.com/HWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care. Upon completion of this activity, participants should be better able to: Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans; Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS; Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia; and Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jeffrey L. Neul, MD, PhD - The Changing Future for Patients With Rett Syndrome and Their Families: Early Diagnosis and New and Emerging Therapies to Reduce the Burdens of Disease 55:33
55:33
Play Later
Play Later
Lists
Like
Liked55:33
Go online to PeerView.com/VWR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Due to the rarity of Rett syndrome and overlapping symptoms with other, more common neurodevelopmental disorders, diagnosis is challenging and often missed or delayed. With one Rett-targeted therapy recently approved and others in development, clinicians now have the opportunity to offer not merely symptom management but potential clinical improvement. This PeerView case-based activity is designed to improve your ability to recognize, diagnose, and treat patients with Rett syndrome. Each session features a realistic case discussion with expert faculty panelists sharing the evidence that supports clinical decisions for timely diagnosis and early initiation of multidisciplinary management and targeted therapy as appropriate. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in patients demonstrating subtle signs and symptoms; Employ evidence-based, age-appropriate care for patients with Rett syndrome in alignment with consensus management guidelines; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of new and emerging therapies for the treatment of Rett syndrome.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP / Peter A. Lio, MD - Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis 33:00
33:00
Play Later
Play Later
Lists
Like
Liked33:00
Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Richard Keen, PhD, FRCP, Edna E. Mancilla, MD - Can YOU Avoid Iatrogenic Harm? Understanding and Identifying Fibrodysplasia Ossificans Progressiva 1:04:30
1:04:30
Play Later
Play Later
Lists
Like
Liked1:04:30
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NYY865. CME credit will be available until August 30, 2024. Can YOU Avoid Iatrogenic Harm? Understanding and Identifying Fibrodysplasia Ossificans Progressiva In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and International Fibrodysplasia Ossificans Progressiva Association ,Progressive Osseous & Heteroplasia Association ,The American Society for Bone and Mineral Research. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner Richard Keen, PhD, FRCP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; Regeneron Pharmaceuticals Inc.; and UCB, Inc. Grant/Research Support from Incyte; Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; and Regeneron Pharmaceuticals Inc. Speaker for Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; Regeneron Pharmaceuticals Inc.; and UCB, Inc. Co-Chair/Planner Edna E. Mancilla, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Ipsen Biopharmaceuticals, Inc./Clementia Pharmaceuticals. Grant/Research Support from Incyte. Patient/Planner Erin Danzer has no financial interests/relationships or affiliations in relation to this activity. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Boni Elizabeth Elewski, MD, Mark Lebwohl, MD - Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares 58:34
58:34
Play Later
Play Later
Lists
Like
Liked58:34
Go online to PeerView.com/NJA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP. Upon completion of this activity, participants should be better able to: Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations; Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis; Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action; and Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jaime Almandoz, MD, MBA, FTOS - Leading the Charge to Change the Obesity Narrative: Supporting Primary Care to Improve Weight Management Discussions, Diagnosis, and Decisions 57:11
57:11
Play Later
Play Later
Lists
Like
Liked57:11
Go online to PeerView.com/XZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the United States, the prevalence of obesity has been steadily increasing. Despite the number of obesity specialists in the United States multiplying five-fold from 2011 to 2019, there is an inadequate number of trained professionals to treat all people requiring obesity-targeted care. Primary care is often the first and only touch point for many people with obesity (PwO), and there is a need to equip and prepare primary care professionals (PCPs) to treat this patient population with empathetic, effective, and evidence-based obesity-targeted care. This PeerView Train-the-Trainer MasterClass activity combines concise overviews of essential evidence with training resources to help you, as an obesity specialist, lead the charge to educate your PCP colleagues. Using practical exercises, experts provide guidance on strategies and tactics you can use to create your own training workshop for PCPs. In addition to the Train-the-Trainer video, participants also have free access to a slide library, surveys, and practice aids to create their own independent training workshop. Upon completion of this activity, participants should be better able to: Address misperceptions and weight biases held by many PCPs to minimize the downstream effects and complications in people with obesity; and Assist PCPs in combating clinical inertia and encouraging early intervention in people with or at risk for obesity…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Stacy E. Croteau, MD, MMS, Steven W. Pipe, MD - Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategies in Hemophilia A 56:43
56:43
Play Later
Play Later
Lists
Like
Liked56:43
Go online to PeerView.com/SFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new PeerView activity based on a recorded symposium at the 75th Annual Bleeding Disorders Conference, an expert panel engages in thought-provoking, interactive case-based discussions and offers guidance on how healthcare professionals can address real-world challenges of hemophilia A management with novel EHL FVIII prophylaxis. Our experts provide guidance on critically evaluating the latest clinical evidence, tailoring treatment plans to individual patient needs, and navigating the challenges associated with patient adherence, access to therapy, and transitioning patients from conventional options (eg, SHL FVIII replacement therapy) to innovative EHL FVIII prophylaxis. Access this activity now to see if you are prepared to lead the way to better outcomes for hemophilia A! Upon completion of this activity, participants should be better able to: Summarize the mechanistic differences and latest clinical evidence with novel EHL FVIII replacement agents for hemophilia A; Identify unmet medical needs and barriers to optimal prophylaxis of hemophilia A; Integrate novel EHL FVIII replacement therapies into personalized treatment regimens for patients with hemophilia A based on clinically-relevant factors, current evidence, and guideline recommendations, among other considerations; and Develop strategies to address practical aspects of care, such as dosing, safety considerations, monitoring, patient education, and adherence counseling, when using novel EHL FVIII agents…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Kara Mayes, MD, FAAFP / Jay H. Shubrook, DO, FAAFP, FACOFP - Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals 1:01:06
1:01:06
Play Later
Play Later
Lists
Like
Liked1:01:06
Go online to PeerView.com/PQU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox! Upon completion of this activity, participants should be better able to: Intensify treatment in people with T2D consistent with the latest guidelines, available evidence, and shared decision-making principles to control glycemia and weight to optimize outcomes and avoid long-term complications; Explain the rationale for targeting weight and establish personalized weight loss goals as a treatment priority for comprehensive T2D management; and Counsel people with T2D about the relationship between obesity and diabetes and the importance of achieving and maintaining a healthy weight as a T2D treatment priority.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Michael Levy, MD, PhD - Test Your Knowledge: Are You Missing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD)? 35:28
35:28
Play Later
Play Later
Lists
Like
Liked35:28
Go online to PeerView.com/CTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) was identified as a distinct demyelinating disease entity only recently. Prior to this characterization of MOGAD, many patients were considered to have a variant of MS, NMOSD, or other neurologic condition. Now an international panel of experts has proposed diagnostic criteria that, when validated, promise to improve MOGAD diagnostic accuracy and confidence. This is particularly important, given that several clinical trials are investigating potential treatments for MOGAD. This unique PeerView activity will use problem-based educational interventions to expose learners to the science and clinical experience behind accurate diagnosis and best practices in management of MOGAD. You will be able to employ optimal clinical decision-making for your patients with MOGAD that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Explain the diagnostic criteria for MOGAD as proposed by the International MOGAD Panel; Employ recommended diagnostic tools (eg, the MOG antibody test, relevant MRI findings) to identify MOGAD and distinguish it from other demyelinating diseases; and Implement therapeutic strategies to provide acute treatment and relapse prevention in patients with MOGAD.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Stephen P. Salloway, MD, MS - Case by Case: Actioning Patient-Centered Strategies for Risk Assessment, Diagnosis, and Management of Amyloid-Related Imaging Abnormalities (ARIA) 1:03:11
1:03:11
Play Later
Play Later
Lists
Like
Liked1:03:11
Go online to PeerView.com/QVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age and increasing as the population ages. After almost two decades without a new AD treatment, recent advances in disease-modifying therapies—including the accelerated FDA approval of two amyloid-targeting therapies (ATTs) and a third in late-stage development—have introduced the possibility of slowed disease progression and improved patient outcomes. Furthermore, significant advances have been made in identifying and testing biomarkers for AD that may aid in early diagnosis, proper treatment selection, and assessment of therapeutic response. The latter is increasingly important given the need to monitor for amyloid-related imaging abnormalities (ARIA) in patients being prescribed ATTs for mild cognitive impairment due to AD or mild AD dementia. With the rapid developments in AD assessment and treatment, it is vitally important to increase awareness of ARIA among healthcare providers. In this activity, based on a recent live symposium, AD experts pair compelling, real-world case scenarios with practice-changing evidence to illustrate how to select patients for treatment with ATTs, how to discuss the risk of ARIA with patients, and how to monitor, recognize, and manage ARIA in patients once they start treatment. Upon completion of this activity, participants should be better able to: Select appropriate patients for treatment with amyloid-targeting therapies (ATTs); Appropriately monitor for and manage amyloid-related imaging abnormalities (ARIA) in patients taking ATTs for the treatment of early-stage Alzheimer’s disease (AD); and Implement effective communication strategies to educate patients and caregivers about ARIA.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 David J. Kuter, MD, DPhil / Cindy Neunert, MD, MSCS - New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes 1:19:51
1:19:51
Play Later
Play Later
Lists
Like
Liked1:19:51
Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable remissions, the challenges of multiple relapses, and symptoms such as fatigue and anxiety over bleeding; Cite the mechanistic rationale, efficacy, and safety evidence supporting the use of BTK inhibitors in patients with previously treated ITP; Integrate newer therapeutics, including BTK inhibitor-based options, into the management of adults and adolescents with persistent and chronic ITP; and Address practical aspects related to the use of innovative therapeutics in ITP, including management of unique dosing and safety considerations; attention to patient quality of life; and provision of education to patients requiring therapy for relapsed disease.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Babafemi O. Taiwo, MBBS - Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment 35:46
35:46
Play Later
Play Later
Lists
Like
Liked35:46
Go online to PeerView.com/JDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Bradley S. Miller, MD, PhD - Improving Outcomes in Pediatric Growth Hormone Deficiency With Effective Diagnosis and Personalized Management Strategies 1:04:06
1:04:06
Play Later
Play Later
Lists
Like
Liked1:04:06
Go online to PeerView.com/ZAB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of recombinant human growth hormone (rhGH) therapy has facilitated wider treatment of growth hormone deficiency. In this CME-certified MasterClass & Practicum video activity, expert faculty will review current guidelines for pediatric growth hormone deficiency diagnosis, growth hormone therapy indications, and characteristics of available and emerging growth hormone therapies. Tune in today to increase your knowledge and competence on the diagnosis and management of growth hormone deficiency with rhGH therapy, including long-acting growth hormone agents, and gain a better understanding of how to address patient needs. Upon completion of this activity, participants should be better able to: Utilize relevant diagnostic tests to provide timely diagnosis of pediatric patients suspected to have growth hormone deficiency; Compare the clinical characteristics and supporting evidence (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) for various options in growth hormone therapy; and Incorporate growth hormone therapy into personalized management plans to address pediatric patient challenges such as dosage concerns, administration, adherence, and monitoring.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Philip Harvey, PhD - Visualizing a New Horizon: Emerging Advances in the Treatment of Cognitive Impairment Associated With Schizophrenia 31:05
31:05
Play Later
Play Later
Lists
Like
Liked31:05
Go online to PeerView.com/FMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore recent advances in the management of cognitive impairment associated with schizophrenia (CIAS) and learn how to implement current and emerging treatment strategies into individualized care plans to improve your patients’ outcomes and quality of life. Upon completion of this activity, participants should be better able to: Summarize the burdens of cognitive impairment in patients with schizophrenia and its impact on patient outcomes and quality of life; Describe the pathophysiology of CIAS, emphasizing the difference between negative symptoms and cognitive impairment; and Implement current and emerging treatment strategies for CIAS, taking into account the latest evidence and patient treatment goals, preferences, and unmet needs.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Rohit Loomba, MD, MHSc - Hope Is on the Horizon for Nonalcoholic Steatohepatitis: Leveraging the Power of Next Generation Monitoring and Pharmacotherapies 25:47
25:47
Play Later
Play Later
Lists
Like
Liked25:47
Go online to PeerView.com/RVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses NAFLD and NASH as metabolic diseases and potential therapeutic targets for patients with the conditions. Upon completion of this activity, participants should be better able to: Describe the disease pathways and mechanisms that define NAFLD/NASH as metabolic diseases; Discuss the pathophysiology and role of GLP-1 as a therapeutic target in NAFLD/NASH and other metabolic conditions; Use noninvasive tests and biomarkers to monitor NAFLD/NASH disease progression; and Initiate early guideline-driven and pathway-driven management with available and emerging pharmacotherapies to delay NAFLD/NASH progression and improve outcomes for patients…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Steven W. Pipe, MD - Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products 55:05
55:05
Play Later
Play Later
Lists
Like
Liked55:05
Go online to PeerView.com/WEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you aware of the evidence supporting the use of innovative EHL FVIII therapies for the prophylactic management of hemophilia A? Find out in this activity based on a “MasterClass” event recorded at the 2023 Congress of the International Society on Thrombosis and Haemostasis. Hear what hemophilia experts are saying about the latest clinical evidence that supports the use of innovative EHL FVIII therapy in hemophilia as they link the data directly to case-based decisions in real-world settings—with a goal of clearly illustrating the practicalities of safely using novel and emerging factor products. The experts also provide guidance on implementing evidence-based protocols and preventing and managing complications in the context of EHL FVIII therapy. Upon completion of this activity, participants should be better able to: Assess the latest safety, efficacy, and pharmacokinetic data among currently approved and emerging EHL FVIII products for prophylaxis of hemophilia A; Develop personalized prophylactic regimens with novel and emerging EHL FVIII products based on patient- and disease-specific factors; and Manage practical aspects of care, such as patient education, adherence counseling, monitoring, and AE management, when using novel and emerging EHL FVIII products for prophylaxis of hemophilia A…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM 58:51
58:51
Play Later
Play Later
Lists
Like
Liked58:51
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 John B. Buse, MD, PhD - Scoring Comprehensive T2DM Management Goals: Examining the Multifaceted Effects of GLP-1 Receptor Agonists 1:04:27
1:04:27
Play Later
Play Later
Lists
Like
Liked1:04:27
Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you’ll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Naval Daver, MD - Pushing Innovation in AML: Real-World Integration of Modern Therapeutics Into Personalized Patient Management 1:16:27
1:16:27
Play Later
Play Later
Lists
Like
Liked1:16:27
Go online to PeerView.com/PYA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Newer treatment modalities for acute myeloid leukemia (AML) have rapidly eclipsed the decades-long cytarabine-based standard of care and helped clinicians adopt more personalized management using innovative cytotoxic platforms, targeted agents (including FLT3, BCL2, and IDH inhibitors), and other unique management strategies. Clinicians can now improve patient outcomes across all AML treatment settings, while at the same time selecting the most potent, personalized option that can be designed to address a given patient’s needs. This “Seminars and Tumor Board” activity, adapted from our recent live event held at the 2023 ASCO Annual Meeting and developed in collaboration with the HealthTree Foundation for Acute Myeloid Leukemia, reveals how modern baseline assessment paired with cutting-edge prognostication has pushed patient management to new heights of innovation and changed the management of patients with AML with therapeutically relevant features (such as FLT3 or IDH mutations), patients presenting without driver mutations, or individuals with comorbid illnesses or higher-risk features. Join the AML experts for a real-world “Tumor Board”–style discussion of how the latest evidence can inform your practice. Upon completion of this activity, participants should be better able to: Summarize baseline patient-related and disease-related factors, including age, comorbidities, functional status, and cytogenetic/mutational findings, that can influence prognostication and treatment selection in AML; Cite current evidence supporting the personalized use of novel treatment modalities, including new cytotoxic platforms, targeted agents, immunotherapy, and epigenetic strategies, for the management of newly diagnosed or relapsed/refractory AML; Integrate novel therapeutics into the personalized team-based management of AML according to the results of baseline assessment, presence or absence of targetable mutations, functional status, or AML subtype; and Address care delivery considerations, including optimized dosing and safety management, when caring for patients with AML…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Martina J. Porter, MD - How Do You Diagnose and Treat Hidradenitis Suppurativa? Compare Your Approach With the Experts’ 1:02:23
1:02:23
Play Later
Play Later
Lists
Like
Liked1:02:23
Go online to PeerView.com/MYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hidradenitis suppurativa (HS) is a chronic and recurrent inflammatory dermatologic condition that can take a long time to diagnose because of its relative rarity and long list of differential diagnoses. In the meantime, the pain and embarrassment caused by discharge and disfiguration severely decrease the quality of life for people who are impacted. Fortunately, there are a number of biologic therapies that are approved to treat HS or are in Phase 2 and 3 trials, such as inhibitors of IL-1, IL-17F and IL-17A. This activity is designed to reduce the time to diagnosis, educate clinicians on the burden their patients face, and understand the need for emerging therapies with greater efficacy. Two faculty experts will walk you through HS management and treatment protocols, with a focus on improving your knowledge and competence to incorporate new and emerging therapies into the management of this complex disease. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and diagnostic challenges to make a timely and accurate diagnosis of hidradenitis suppurativa; Describe the burdens of disease and impact on quality of life for patients with hidradenitis suppurativa; Recognize the limitations of current therapies for hidradenitis suppurativa; and Apply clinical safety and efficacy data on emerging novel treatments for patients with hidradenitis suppurativa…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Allison Agwu, MD, ScM, FAAP, FIDSA - Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and… 43:38
43:38
Play Later
Play Later
Lists
Like
Liked43:38
Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Charles L. Daley, MD - Improving Time to Diagnosis of Non-Cystic Fibrosis Bronchiectasis: The Importance of the Radiologist in Fulfilling Unmet Needs of Patients 55:09
55:09
Play Later
Play Later
Lists
Like
Liked55:09
Go online to PeerView.com/TXG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American Roentgen Ray Society 2023 Annual Meeting, a radiologist and pulmonologist explain the importance of early diagnosis in non-cystic fibrosis bronchiectasis (NCFBE) and explore the intricacies of CT imaging interpretation as a tool for optimizing care for bronchiectasis. These experts also share evolving insights into the pathophysiology of bronchiectasis that have led to the development of novel and emerging therapies, in particular DPP-1 inhibitors, to address underlying inflammation associated with the disease. See if you are up to date on the latest diagnosis, treatment, and management innovations for your patients with NCFBE and receive CME/MOC credit today! Upon completion of this activity, participants should be better able to: Describe the disease burden of non-cystic fibrosis bronchiectasis (NCFBE) as a chronic progressive condition and the importance of imaging for accurate diagnosis; Recognize CT features of NCFBE to facilitate diagnosis and allow for intervention; and Explain how recent insights into the underlying mechanisms of NCFBE might address unmet treatment needs for patients with NCFBE…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Juan Pablo Frías, MD - Case in Point: Addressing Practical Questions to Improve Long-Term Outcomes in Patients With Obesity 57:29
57:29
Play Later
Play Later
Lists
Like
Liked57:29
Go online to PeerView.com/KEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Early intervention is central to reducing excess weight gain and the risk of obesity-related comorbidities, yet many people never receive a formal diagnosis or specialty obesity care. With this in mind, how can clinicians best support this patient population? Endocrinologists, in particular, are on the front lines of managing and treating this complex disease. In this PeerView inReview, an expert uses patient videos to explain what you need to know about effective, compassionate patient communication and offers practical guidance on how to best integrate anti-obesity medications into patient care to improve long-term outcomes. Upon completion of this activity, participants should be better able to: Prioritize obesity as a chronic, progressive disease that requires individualized, long-term management; Initiate nonjudgmental conversations with individuals living with obesity and engage in effective shared decision-making discussions to achieve sustained weight loss; Compare the mechanism of action, efficacy, and safety of approved and emerging medications for the long-term management of obesity; and Identify people with obesity who could benefit from treatment with anti-obesity medications…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Shmuel Shoham, MD / Ghady Haidar, MD - What’s New, and What’s Next? Customizing COVID-19 Prevention Approaches in Transplant Patients to Increase Uptake, Access, and Efficacy 57:50
57:50
Play Later
Play Later
Lists
Like
Liked57:50
Go online to PeerView.com/ERY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hundreds of thousands of organ transplant recipients living in the United States, who must take immunosuppressive medication, are at an increased risk of COVID-19 infection. Tixagevimab co-packaged with cilgavimab has lost its emergency use authorization as prevention for immunocompromised patients because of its lack of efficacy against newer variants. In the absence of prevention agents (other than vaccines) and because the prevention of COVID-19 is shifting to a more personalized, patient-specific approach, the complexity of clinical decision-making has increased. Additionally, patients may face barriers in obtaining COVID-19 prevention. In this activity, based on a recent live symposium, expert faculty and a patient advocate discuss strategies to improve the uptake of COVID-19 prevention and increase patient and clinician engagement and how to develop a plan to customize COVID-19 prevention at point of care for patients needing prevention. In addition, they look at creating strategies for patients in order to help in overcoming real-time barriers. Upon completion of this activity, participants should be better able to: Improve the uptake of COVID-19 prevention and increase patient and clinician engagement in following science-based evidence; Develop a plan to customize COVID-19 prevention at point of care for patients needing protection against the virus using evidence-based recommendations and guidelines; and Facilitate patient access to needed COVID-19 prevention by creating strategies to overcome real-time barriers.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists 57:21
57:21
Play Later
Play Later
Lists
Like
Liked57:21
Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities; Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB; Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology; and Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Elena Elimova, MD, M.Sc., FRcPC - Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care 1:02:28
1:02:28
Play Later
Play Later
Lists
Like
Liked1:02:28
Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular testing, including HER2 expression, and its role in treatment selection for patients with HER2-positive GI cancers; Implement personalized treatment strategies based on molecular findings, current evidence and recommendations, and patient-specific factors when managing HER2-expressing GI cancers; and Apply practical strategies to manage and mitigate treatment-related AEs associated with HER2-targeting agents when managing BTC and GEA.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jessica Ailani, MD, FAHS, FAAN, FANA - Breakthrough Therapies for the Prevention and Acute Treatment of Migraine: Addressing Unmet Needs in the Primary Care Setting 28:40
28:40
Play Later
Play Later
Lists
Like
Liked28:40
Go online to PeerView.com/MWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Jessica Ailani reviews the latest data on therapies for acute and preventive management of migraine, with a focus on personalized treatment. A patient interview and 3D animation are also part of this engaging video program. Upon completion of this activity, participants should be better able to: Apply safety and efficacy data related to new acute migraine therapies in clinical decision-making, taking into account patient-reported outcomes; Employ evidence-based prevention strategies for patients with migraine; and Implement individualized treatment plans for patients with migraine.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jaime Almandoz, MD, MBA, FTOS - Practicing What We Preach: Your Role as an Obesity Medicine Specialist, Inspiring Change, and Overcoming Negative Weight Biases to Prioritize the Management of… 1:02:59
1:02:59
Play Later
Play Later
Lists
Like
Liked1:02:59
Go online to PeerView.com/QFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging activity, which is based on a pre-conference workshop held at OMA 2023, experts in obesity management aim to change misperceptions about obesity and explain best practices for treating this chronic condition, which include the importance of anti-obesity medications (AOMs) in achieving individualized weight goals and improving overall health outcomes by reducing the risk and progression of obesity-related comorbidities. Upon completion of this activity, participants should be better able to: Initiate appropriate, unbiased, and nonjudgmental conversations with patients about obesity acknowledging it as a chronic, treatable disease rather than a result of personal irresponsibility; Compare the efficacy and safety profiles of current and emerging anti-obesity medications and their potential to support weight loss efforts and minimize the impact of obesity-related comorbidities; and Employ shared decision-making to implement a comprehensive, individualized treatment plan that incorporates appropriate use of long-term anti-obesity medications to achieve and maintain realistic weight loss in people with obesity.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Monica Tang, MD - Pulling the Plug on Severe Asthma: Taking a Closer Look at an Underrecognized Biomarker to Assess Disease Severity and Tailor Treatment 20:09
20:09
Play Later
Play Later
Lists
Like
Liked20:09
Go online to PeerView.com/SGZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mucus plugging contributes to airway obstruction and death in acute asthma and is increasingly being recognized as a significant contributory factor to persistent, severe asthma. Pulmonologists, allergy and immunology specialists, and other healthcare professionals need to be aware of these latest insights into the pathophysiology of severe asthma to optimally care for their patients. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Dr. Monica Tang will show learners how to identify the presence of airway mucus plugging on HRCT, and she will review the latest evidence with regard to mucus plugging treatment. Upon completion of this activity, participants should be better able to: Explain the role of mucus plugging as a contributory factor to airway obstruction and symptoms in severe asthma and its implications for treatment; Identify the presence of airway mucus plugging on HRCT according to current expert recommendations; and Apply recent insights into the role of mucus plugging, as well as the latest clinical evidence, to the selection of treatment for patients with severe asthma…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Nicholas K. Mollanazar, MD, MBA - Targeting Disease Pathophysiology to Achieve Effective Treatment in Prurigo Nodularis 26:14
26:14
Play Later
Play Later
Lists
Like
Liked26:14
Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don’t forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anna Chodos, MD, MPH - Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care 58:14
58:14
Play Later
Play Later
Lists
Like
Liked58:14
Go online to PeerView.com/XUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process. Upon completion of this activity, participants should be better able to: Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD; Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns; and Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to… 57:10
57:10
Play Later
Play Later
Lists
Like
Liked57:10
Go online to PeerView.com/RZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care. Upon completion of this activity, participants should be better able to: Describe the pathophysiology and potential therapeutic targets for IBS-C; Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management; and Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Miguel Regueiro, MD - Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis 50:24
50:24
Play Later
Play Later
Lists
Like
Liked50:24
Go online to PeerView.com/FNG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Much progress has been made in defining the genetic abnormalities and associated abnormal pathophysiology underlying the spontaneous and chronic inflammation that characterizes inflammatory bowel disease (IBD). Medications that suppress or modify immune activity form the core of effective treatment for IBD. Sphingosine-1-phosphate (S1P) receptor modulators, a small-molecule therapeutic option, provide a target-specific approach with a favorable safety profile. Multiple S1P receptor modulators are in development, and ozanimod became the first agent in this class to receive FDA approval for the treatment of moderately to severely active ulcerative colitis in 2021. In this activity, based on a recent live symposium, expert faculty will discuss the therapeutic effects of S1P receptor modulators on the underlying pathophysiology of IBD and identify patients with UC who could benefit from treatment with these agents. In addition, the faculty will discuss individualizing treatment using S1P receptor modulators for appropriate patients with IBD in accordance with current evidence and guidelines. Upon completion of this activity, participants should be better able to: Explain how the therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators address the underlying pathophysiology of IBD; Identify patients with UC who could benefit from the use of therapy with S1P receptor modulators; and Individualize treatment using S1P receptor modulators for appropriate patients with UC in accordance with current evidence and guidelines…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Hyman Scott, MD, MPH, David Alain Wohl, MD - Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider 34:15
34:15
Play Later
Play Later
Lists
Like
Liked34:15
Go online to PeerView.com/XFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures. Upon completion of this activity, participants should be better able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives; Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice; Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection; and Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Saira Z. Sheikh, MD, FAAAAI, FACAAI, FACR, Brad Rovin, MD, FASN, FACP - Improving the Patient Experience in SLE and LN: The Intersection of Early Diagnosis, Individualized Treatment, and Culturally… 52:20
52:20
Play Later
Play Later
Lists
Like
Liked52:20
Go online to PeerView.com/JPU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Observed differences in healthcare disparities for patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) have led to the recognition of racial and ethnic minorities as an independent predictor of worse disease outcomes in SLE/LN. Earlier diagnosis, earlier intervention, treatment strategies targeted to clinical remission or low disease activity, and effective communication and collaboration between providers and patients could offer the opportunity to reduce damage, thus improving long-term outcomes. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Drs. Sheikh and Rovin will explore the emerging concept of treat to target, as well as the use of currently available and new/emerging biologic therapies, along with strategies to help learners optimize treatment for patients with SLE/LN. Upon completion of this activity, participants should be better able to: Diagnose SLE, including LN, as early as possible in the course of disease to prevent organ damage and initiate appropriate therapy; Monitor disease activity and response to treatment in SLE and LN based on individual patient needs; Select appropriate treatment for SLE and LN to reduce disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 John Ravits, MD, FAAN - Hope Is on the Horizon for Patients With ALS: Overcoming Diagnostic Difficulties and Exploring Novel Emerging Therapeutic Approaches 28:00
28:00
Play Later
Play Later
Lists
Like
Liked28:00
Go online to PeerView.com/ZXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the importance of early detection and diagnosis of ALS, advances in genetic testing and biomarker development, and current and emerging therapeutic approaches for patients with ALS, as well as the benefits of employing a multidisciplinary approach in managing patients with ALS. Upon completion of this activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis; Apply established criteria to detect and diagnose patients with ALS early in the disease course; Assess key data sets on contemporary and emerging evidence-based treatment options to manage symptoms and improve the quality of life of patients with ALS; and Employ a multidisciplinary team-based approach to optimize the management of ALS based on the individual needs and preferences of each patient.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Neal K. Lakdawala, MD, Anjali Tiku Owens, MD - Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment 56:46
56:46
Play Later
Play Later
Lists
Like
Liked56:46
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Robert C. Green, MD, MPH - Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact… 1:05:19
1:05:19
Play Later
Play Later
Lists
Like
Liked1:05:19
Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Paul Kwo, MD, AGAF, FACG, FAASLD - HBV Is Primary! Your Role in the "Call to Action" to Eliminate Viral Hepatitis By 2030 51:17
51:17
Play Later
Play Later
Lists
Like
Liked51:17
Go online to PeerView.com/AYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses the importance of early detection of hepatitis B virus (HBV) infection and presents current and evolving screening, vaccination, and treatment guidelines. The expert emphasizes the role of primary care providers in managing patients with chronic HBV and in helping to reach the WHO goal of eliminating viral hepatitis as a public health threat by 2030 through vaccination, screening, and patient education. Finally, the expert clarifies when patients with chronic HBV infection should be referred for specialty care. Upon completion of this activity, participants should be better able to: Describe the burden and consequences of HBV infection and how chronic HBV can lead to end-stage liver disease and hepatocellular carcinoma; Identify patients who should be screened for HBV, which tests should be ordered, and how to interpret the results; Manage HBV in the primary care setting in accordance with current evidence and guidelines, recognizing patients who require specialty care referral; and Implement patient-centered and culturally relevant strategies to promote adherence to HBV treatment and retention in care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sean Pokorney, MD, MBA - Episode 1. Looking for Trouble: The Role of Systematic Screening 14:17
14:17
Play Later
Play Later
Lists
Like
Liked14:17
Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sean Pokorney, MD, MBA - Episode 2. Profiles in Comorbidity: Identifying Who Is at High Risk 10:09
10:09
Play Later
Play Later
Lists
Like
Liked10:09
Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sean Pokorney, MD, MBA - Episode 3. Mending the Healthcare System: Reducing Disparities 12:17
12:17
Play Later
Play Later
Lists
Like
Liked12:17
Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sean Pokorney, MD, MBA - Episode 4. The Fear Factor: Mitigating Patients’ Concerns About Anticoagulation 11:43
11:43
Play Later
Play Later
Lists
Like
Liked11:43
Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sean Pokorney, MD, MBA - Episode 5. State-of-the-Art Treatment: Catching Up With Current Guidelines 10:33
10:33
Play Later
Play Later
Lists
Like
Liked10:33
Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sean Pokorney, MD, MBA - Episode 6. Is That Realistic? What We’ve Learned About Anticoagulation Therapy From Real-World Studies 8:29
8:29
Play Later
Play Later
Lists
Like
Liked8:29
Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sean Pokorney, MD, MBA - Episode 7. Marching to Their Own Rhythm: Using Consumer Wearables in AF Diagnosis and Treatment 8:56
8:56
Play Later
Play Later
Lists
Like
Liked8:56
Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners… 39:20
39:20
Play Later
Play Later
Lists
Like
Liked39:20
Go online to PeerView.com/WCP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options. Upon completion of this activity, participants should be better able to: Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis; Identify patients with psoriasis who are most likely to benefit from novel oral treatments; Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines; and Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smarter Approaches for Diagnosing HoFH 34:53
34:53
Play Later
Play Later
Lists
Like
Liked34:53
Go online to PeerView.com/BPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While homozygous familial hypercholesterolemia (HoFH) is associated with development of atherosclerotic cardiovascular disease in childhood, early recognition and treatment of this inherited disease can improve outcomes for patients. In this animated activity provided by PeerView in collaboration with the Family Heart Foundation, a cardiologist describes the impact of this rare disease on patients and their families, presents strategies for recognizing signs and symptoms of HoFH, and reviews guidelines for genetic screening and referral of patients and their families to appropriate experts and resources for support. Additionally, two patients share their experiences of living with HoFH. Upon completion of this activity, participants should be better able to: Describe the consequences of undiagnosed and untreated HoFH from the patient’s perspective; Distinguish hallmark signs, symptoms, and family history differentiating HoFH from other disorders; and Employ current guidelines and support resources to direct patients with suspected HoFH to appropriately qualified care providers.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - Medicine in Motion: Visual Guide to a New Generation in Care for Patients With Hypertrophic Cardiomyopathy 38:00
38:00
Play Later
Play Later
Lists
Like
Liked38:00
Go online to PeerView.com/KYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The visual guide to hypertrophic cardiomyopathy (HCM) you’ve been waiting for is here! In contemporary care, patients with HCM have options that may reduce the need for invasive treatments. This engaging presentation is perfect for both visual and auditory learners to update their understanding of HCM, tune in to the signs and symptoms that should raise suspicion, and learn best practices to confirm a diagnosis of HCM. Once diagnosed, you’ll need to know the latest data on cardiac myosin inhibitors and practical guidance for integrating them into patient care. This activity delivers on all of the above—set aside some time and click “play” today! Upon completion of this activity, participants should be better able to: Recognize clinical characteristics and/or features that suggest the presence of HCM; Accurately diagnose patients with suspected HCM using expert guidance and the latest recommendations to promote early identification and treatment; and Personalize the medical treatment of HCM using strategies with disease-modifying potential based upon the latest efficacy and safety evidence and consistent with current prescribing and monitoring recommendations to ensure long-term patient safety and improve clinical outcomes.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH 25:50
25:50
Play Later
Play Later
Lists
Like
Liked25:50
Go online to PeerView.com/BNB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert on homozygous familial hypercholesterolemia (HoFH) discusses the latest data for novel lipid-lowering therapies and offers strategies for individualizing treatment regimens to improve outcomes for patients with HoFH. Upon completion of this activity, participants should be better able to: Apply standards of care to initiate and escalate lipid-lowering therapies in patients with HoFH; Distinguish the therapeutic characteristics of recently approved HoFH therapies according to their mechanisms of action; and Evaluate the benefits and limitations of approved HoFH therapies to individualize patient care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Marwan Sabbagh, MD, FAAN - Translating the Latest Research Advances Into Routine Care for Alzheimer’s Disease: Preparing Dementia Specialists With the Latest Strategies to Support Early Diagnosis… 1:03:08
1:03:08
Play Later
Play Later
Lists
Like
Liked1:03:08
Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer’s disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer’s disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP - Improving Outcomes for Hospitalized Patients with COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice 1:00:08
1:00:08
Play Later
Play Later
Lists
Like
Liked1:00:08
Go online to PeerView.com/SRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the availability of testing, vaccines, and treatments, COVID-19 remains a threat—no one can predict when a new strain might surface and many questions remain. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic to critical and fatal illness. Most symptomatic infections are mild; however, a significant number of patients have severe disease requiring hospitalization. Hospitalization and death are more likely in high-risk populations, including older people, individuals with underlying medical problems, and those affected by systemic health and social inequities (ie, minorities, immigrant populations, people of low socioeconomic status, and the disabled). Therapies such as antiviral agents and monoclonal antibodies are available in the United States and Europe for the treatment of COVID-19; however, there are challenges with determining which hospitalized patients may be best suited for which treatment. In this activity, based on a recent live web broadcast, a panel of experts explores strategies to improve outcomes for COVID-19 in the hospital setting, with a focus on designing individualized treatment plans based on current guidelines, evolving evidence, and patient-specific factors. The panel also discusses how differences in drug access and treatment protocols impact the healthcare team in regards to providing individualized treatment programs for patients hospitalized with COVID-19. Upon completion of this activity, participants should be better able to: Assess patients with COVID-19 to make appropriate treatment recommendations based on disease severity; Differentiate therapies for COVID-19 based on the latest safety and efficacy data from clinical trials; Collaborate with the healthcare team to design timely and individualized treatment plans for hospitalized patients with COVID-19 disease based on current guidelines, evolving evidence, and patient-specific factors; and Discuss the clinical implications of prolonged/persistent viral replication in severe COVID-19…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 April W. Armstrong, MD, MPH - Understanding TYK2’s Role in Psoriasis Pathogenesis and Taking a Practical Approach to Realizing Its Potential in the Clinic 49:15
49:15
Play Later
Play Later
Lists
Like
Liked49:15
Go online to PeerView.com/XMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis, a chronic inflammatory disease that affects up to 1 in 20 people worldwide, can drastically impact a patient's quality of life and health. The number of therapies for patients with moderate-to-severe psoriasis has grown steadily over the past 2 decades. Biologic immunotherapies have been the primary agents to gain approval, while small-molecule therapies have lagged in development. Deucravacitinib is a newly approved oral small molecule that inhibits the activity of TYK2, a member of the JAK family. Deucravacitinib allosterically inhibits TYK2 activity by binding to the regulatory domain rather than the catalytic domain. Binding in this way gives deucravacitinib greater specificity for TYK2 versus the closely related JAK1/2/3. Deucravacitinib has demonstrated safety and efficacy in moderate-to-severe chronic plaque psoriasis in two phase 3 pivotal trials (POETYK PSO-1 and PSO-2). Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 response rates were significantly higher with deucravacitinib versus placebo or apremilast. In this activity, based on a recent live symposium, expert faculty discuss the clinical implications of targeting TYK2 in psoriasis, as well as strategies to identify patients for whom inhibition of TYK2 would be an appropriate treatment option based on available data. In addition, the faculty delve into the importance of shared decision-making in formulating personalized management plans for patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of moderate-to-severe psoriasis as it relates to selective targeting of TYK2; Identify patients with psoriasis for whom inhibition of TYK2 would be an appropriate treatment option based on available efficacy and safety data and practice guidelines; and Develop personalized management plans for patients with psoriasis using principles and tools of shared decision-making, empowering patients to participate in treatment decisions and remain adherent to therapies…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Evan S. Dellon, MD, MPH - What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice 37:09
37:09
Play Later
Play Later
Lists
Like
Liked37:09
Go online to PeerView.com/TGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life. Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising. This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice. Upon completion of this activity, participants should be better able to: Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease; Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team; and Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Marwan Sabbagh, MD, FAAN - Gearing Up for Plasma Biomarkers in the Clinic: Real-World Strategies to Facilitate the Timely and Accurate Neuropathological Diagnosis of Alzheimer’s Disease 1:03:03
1:03:03
Play Later
Play Later
Lists
Like
Liked1:03:03
Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Prof. Hans Gelderblom, MD - New Evidence Now for Targeted Therapy in TGCT 13:40
13:40
Play Later
Play Later
Lists
Like
Liked13:40
Go online to PeerView.com/DNP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your skills in managing tenosynovial giant cell tumors (TGCT)—particularly in light of updated phase 3 evidence supporting systemic treatment? Find out in this final part of an educational series on TGCT, where an expert in the field reviews current standards of care and provides updates from a major clinical trial that supports the use of targeted options in conjunction with established multimodal treatment protocols for TGCT management. Upon completion of this activity, participants should be better able to: Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients where continued surgery is unlikely to produce clinical benefits; and Manage safety and dosing considerations with targeted agents in the setting of TGCT.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Petros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All 1:01:20
1:01:20
Play Later
Play Later
Lists
Like
Liked1:01:20
Go online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, a panel of leading bladder cancer experts pairs important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity will highlight strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for the use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Using patient cases drawn from clinical practice and interactivity that allows participants to see how their treatment choices compare with their colleagues, the faculty will address the mechanistic rationale for these new therapies, therapeutic decision-making, and AE mitigation strategies. Upon completion of this activity, participants should be better able to: Synthesize new evidence on multi-faceted strategies for bladder cancer management based on modern immunotherapeutic agents, small molecule targeted therapies, and antibody–drug conjugates, among others; Integrate novel and emerging therapeutic approaches into personalized treatment plans for patients with bladder cancer, considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Implement evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac… 1:37:57
1:37:57
Play Later
Play Later
Lists
Like
Liked1:37:57
Go online to PeerView.com/SFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) have had a strikingly positive impact on the treatment of a range of cancer types by blocking intrinsic downregulators of the immune response to increase antitumor immunity. A number of ICIs and ICI-based combinations have been approved for use in many solid and liquid malignancies, and intense research efforts promise to expand their role in advanced cancers and early-stage, curative-intent settings. While immunotherapy has become a pillar of cancer treatment and is considered safe, ICIs are associated with a spectrum of unique toxicities termed immune-related adverse events (irAEs). These irAEs can affect any organ system in the body, including the heart and cardiovascular system, occur at any point during or after treatment, and vary in presentation from mild to severe, and sometimes life threatening. Cardiac pathology attributed to irAEs include myocarditis, cardiomyopathy, pericardial disease, arrhythmias and conduction disease, impaired ventricular function with heart failure, and vasculitis. Autoimmune myocarditis is the most common and best characterized cardiac irAE to date. This activity, based on a PeerView Live Clinical Consults cardio-oncology symposium, provides essential guidance for prompt identification and initiation of treatment of irAEs. In the current era of cancer immunotherapy, healthcare professionals must develop a high level of vigilance and be able to correctly and rapidly manage and monitor patients with cancer exhibiting symptoms of possible cardiac irAEs to ensure the best possible outcomes. The expert faculty presents management algorithms, real-world case scenarios, and practical challenges related to multidisciplinary coordination of care to improve collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Review the prevalence, biologic mechanisms, burden, and consequences of the development of cardiac immune-related adverse events (irAEs) during or after treatment with cancer immunotherapies; Apply algorithms, practical tools, and available therapies based on the latest clinical evidence and recommendations for baseline risk assessment, identification, diagnosis/differential diagnosis, treatment, and management of cardiac irAEs; and Utilize effective shared decision-making and team-based approaches to facilitate multidisciplinary and interprofessional collaboration and improve clinician-patient communication and outcomes for patients at risk of or experiencing cardiac irAEs…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Catherine M. Broome, MD - Following the Diagnostic Pathway for Cold Agglutinin Disease 30:43
30:43
Play Later
Play Later
Lists
Like
Liked30:43
Go online to PeerView.com/UHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), as well as appropriate strategies to differentiate cold agglutinin disease from other forms of AIHA in providing optimal care for patients. Upon completion of this activity, participants should be better able to: Recognize the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), and Employ appropriate strategies to differentiate cold agglutinin disease (CAD) from other forms of autoimmune hemolytic anemia (AIHA) to provide optimal care for patients.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World 58:44
58:44
Play Later
Play Later
Lists
Like
Liked58:44
Go online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to benefit. In PeerView’s latest Clinical Consults video, an expert panel will share their insight for effectively integrating different treatment approaches linked to the latest evidence and expand upon real-life experiences and practical guidance. Upon completion of this activity, participants should be better able to: Evaluate evidence on the role of novel and emerging therapeutics, efficacy, and safety for patients with RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, and patient-, disease- and treatment-specific factors; and Integrate evidence-based strategies and best practices to recognize, mitigate, and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE? 6:47
6:47
Play Later
Play Later
Lists
Like
Liked6:47
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly 11:27
11:27
Play Later
Play Later
Lists
Like
Liked11:27
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long? 13:35
13:35
Play Later
Play Later
Lists
Like
Liked13:35
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 4: How Can We Talk About VTE to Our Patients? 9:11
9:11
Play Later
Play Later
Lists
Like
Liked9:11
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 5: Knocking Down Barriers in Transitions of Care 12:49
12:49
Play Later
Play Later
Lists
Like
Liked12:49
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 6: What Is Real-World Evidence and How Is It Relevant and Important in VTE? 7:17
7:17
Play Later
Play Later
Lists
Like
Liked7:17
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity? 10:13
10:13
Play Later
Play Later
Lists
Like
Liked10:13
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 8: VTE in Cancer: How Concerning Is It and What Do We Do About It? 11:56
11:56
Play Later
Play Later
Lists
Like
Liked11:56
Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Daniel J. George, MD - Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and… 48:41
48:41
Play Later
Play Later
Lists
Like
Liked48:41
Go online to PeerView.com/ZYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care. Upon completion of this activity, participants should be better able to: Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes; Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors; and Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Peter H. Jones, MD, MNLA, R. Scott Wright, MD - Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel… 57:14
57:14
Play Later
Play Later
Lists
Like
Liked57:14
Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition? 32:34
32:34
Play Later
Play Later
Lists
Like
Liked32:34
Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 R. Scott Wright, MD - Diagnosing and Treating Hyperlipidemia in Family Medicine: Exploring the Latest Clinical Evidence and the Role of Novel PCSK9-Targeting Therapies 53:01
53:01
Play Later
Play Later
Lists
Like
Liked53:01
Go online to PeerView.com/QCN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hyperlipidemia discusses evidence-based strategies for diagnosing and individualizing treatment plans with PCSK9-targeting agents to improve patient outcomes. Upon completion of this activity, participants should be better able to: Perform a diagnostic evaluation based on current clinical guidelines for the treatment of hyperlipidemia; Assess the mechanisms of action, efficacy, and safety of PCSK9-targeting agents designed to further reduce lipid levels in patients with hyperlipidemia; Identify patients who may benefit from treatment with PCSK9-targeting therapies; and Recognize the role of multidisciplinary collaboration and patient education to optimize outcomes in patients with hyperlipidemia.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Richard K. Bogan, MD, FCCP, FAASM - Managing Disorders of Hypersomnolence: Reducing Patient Burdens, Protecting Patient Health 30:45
30:45
Play Later
Play Later
Lists
Like
Liked30:45
Go online to PeerView.com/JKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert in hypersomnolence discusses the diagnosis, classification, and treatment of narcolepsy and idiopathic hypersomnia. Using real-life cases as examples, the latest data and guidelines are reviewed in juxtaposition with the patients’ stories. Upon completion of this activity, participants should be better able to: Describe how delayed diagnosis of narcolepsy or idiopathic hypersomnia (IH) exacerbates the multifaceted burdens associated with both conditions; Apply International Classification of Sleep Disorders criteria to assess patients who present with excessive daytime sleepiness (EDS) or other signs or symptoms suggesting narcolepsy or IH; and Individualize treatment of narcolepsy and IH, based on the latest clinical evidence and guidelines; patient needs, preferences, and comorbidities; and considerations that affect adherence.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Milind Desai, MD, MBA - Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy? 1:01:14
1:01:14
Play Later
Play Later
Lists
Like
Liked1:01:14
Go online to PeerView.com/KST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM; Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner; Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM; and Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Mark W. Stolar, MD - A Call to Action for Primary Care Professionals: Your Role in Saving the Eyesight of Patients With Diabetes 41:17
41:17
Play Later
Play Later
Lists
Like
Liked41:17
Go online to PeerView.com/FZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Timely screenings and referrals to eye care specialists for diabetic retinopathy (DR) and diabetic macular edema (DME) can make a real difference between good vision and blindness in patients with diabetes. But exactly when should patients with diabetes be screened for DR/DME in the primary care setting and which signs and symptoms should trigger a referral to specialty care? In this activity, based on a recent live virtual symposium, leading experts review guideline recommendations for DR/DME screening and referral in the primary care setting and present realistic patient cases to explore best practices and improve vision outcomes for patients with diabetes. Upon completion of this activity, participants should be better able to: Describe the roles of primary care professionals in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referral to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Jacob P. Thyssen - Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World 57:13
57:13
Play Later
Play Later
Lists
Like
Liked57:13
Go online to PeerView.com/RBZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis is a chronically relapsing skin disease that often begins in early childhood and can persist into adulthood, having a detrimental effect on the lives of patients and their families throughout the lifespan. In this activity, based on a recent live web broadcast, our global experts provide both pediatric and adult dermatologists, allergy/immunology specialists, and other specialty advanced practice providers around the world greater insight into the assessment of disease severity, the use of targeted biologic therapy, and the importance of patient engagement and shared decision-making in the management of atopic dermatitis. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD); Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines; Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy; Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Prof. Arjan Bredenoord - The Latest on New Options for Eosinophilic Esophagitis: Considering Targeted Biologic Therapy 22:58
22:58
Play Later
Play Later
Lists
Like
Liked22:58
Go online to PeerView.com/RFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of eosinophilic esophagitis (EoE)? Hear what was presented at the 30th United European Gastroenterology Week (UEG Week 2022) from Professor Arjan Bredenoord as he shares the latest evidence on novel biologic therapies for EoE and provides practical guidance on their safe and effective integration into clinical practice. Upon completion of this activity, participants should be better able to: Summarize recent clinical research data and treatment guidelines concerning the management of eosinophilic esophagitis (EoE); Integrate the latest clinical evidence concerning novel and emerging targeted therapies into treatment plans for the management of patients with EoE…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Scott T. Tagawa, MD, MS, FACP - Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates 40:00
40:00
Play Later
Play Later
Lists
Like
Liked40:00
Go online to PeerView.com/VRE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver’s perspective on their first-hand experience with the treatment strategies and his journey. These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants should be better able to: Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations; Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care; Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Praneetha Thulasi, MD, Jonathan L. Kaufman, MD - The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity 57:31
57:31
Play Later
Play Later
Lists
Like
Liked57:31
Go online to PeerView.com/AHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to care for your patients with multiple myeloma (MM) who are experiencing ocular complications associated with the latest myeloma treatments? Ophthalmologists play an important in the care of myeloma, and in this PeerView MasterClass & Ophthalmology Case Forum an ophthalmologist and an oncologist highlight the importance of the ophthalmology and oncology connection in myeloma care. Tune in to get practical guidance on the challenges of accurately recognizing and characterizing ocular toxicity in MM patients receiving novel therapy and case-based guidance on collaborating within a modern MM management team, and see how addressing ocular toxicity can contribute to the delivery of highly effective treatment. Upon completion of this activity, participants should be better able to: Recognize the range of novel, therapy-associated ocular complications in the multiple myeloma treatment setting; Integrate proven techniques, including scheduled and routine eye examinations, dry eye prophylaxis, and therapeutic dose adjustment to address ocular toxicity in patients with multiple myeloma; Work collaboratively within oncology-ophthalmology teams to effectively monitor and manage treatment-emergent ocular toxicity in multiple myeloma patients…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy 57:02
57:02
Play Later
Play Later
Lists
Like
Liked57:02
Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jay H. Shubrook, DO, FAAFP, FACOFP - Tools of the Trade: A Practical Guide to Managing NASH 35:26
35:26
Play Later
Play Later
Lists
Like
Liked35:26
Go online to PeerView.com/ACR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses how to utilize the American Gastroenterological Association’s Clinical Care Pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Upon completion of this activity, participants should be better able to: List the disease pathways and mechanisms that define NASH as a metabolic disease; Identify the pathophysiology and role of GLP-1 as a therapeutic target in NASH; Differentially diagnose NASH in a timely manner; Integrate current and emerging agents into early management plans for patients with NASH based on the AGA NASH Clinical Care Pathway…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps 24:17
24:17
Play Later
Play Later
Lists
Like
Liked24:17
Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners’ knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Norman E. Lepor, MD, FACC, FAHA, FSCAI - Envisioning the Future of Hyperlipidemia Management: How Can We Leverage PCSK9-Targeting Therapies to Prevent Primary and Secondary Cardiovascular Events? 34:23
34:23
Play Later
Play Later
Lists
Like
Liked34:23
Go online to PeerView.com/TVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hyperlipidemia management examines the evidence for PCSK9-targeting therapies to prevent primary and secondary cardiovascular (CV) events. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of CV events; Recognize novel mechanisms of action and recent clinical evidence on approved and emerging investigational lipid-lowering therapies that target PCSK9; and Develop treatment protocols using appropriate lipid-lowering therapy including available and emerging agents, alone or in combination, for providing long-term LDL-C reduction and improving adherence.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Steven E. Carsons, MD - Expert Perspectives on Novel Targeted Therapies for Sjögren’s Disease: Hope Is on the Horizon 46:12
46:12
Play Later
Play Later
Lists
Like
Liked46:12
Go online to PeerView.com/HPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss the pathology of Sjögren's disease and potential treatment targets, as well as the clinical criteria and biomarkers used to diagnose the disease and aid in patient classification. Upon completion of this activity, participants should be better able to: Recognize the burden of disease, impact on quality of life, and unmet needs experienced by patients with Sjögren's disease; Describe the pathology of Sjögren's disease and potential treatment targets; Apply clinical criteria, guidelines, and biomarkers to diagnose Sjögren's disease and aid in patient classification; and Identify patients who may derive benefit from novel therapeutic options for Sjögren's disease using clinical trial data and shared decision-making.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of… 1:00:07
1:00:07
Play Later
Play Later
Lists
Like
Liked1:00:07
Go online to PeerView.com/CYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation. You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options. Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction. Upon completion of this activity, participants should be better able to: Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC; Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents; and Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jeffrey L. Neul, MD, PhD - Encouraging News in Rett Syndrome: Steps Towards a Timely, Accurate Diagnosis and Treatment Breakthroughs 27:53
27:53
Play Later
Play Later
Lists
Like
Liked27:53
Go online to PeerView.com/QSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Rett syndrome discusses the diagnosis and management of this rare disease, as well as the latest data on emerging treatment options. A 3D animation offers an overview of MECP2 mutation, hypothesized to be a major contributor to the CNS manifestations of Rett syndrome. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in infants demonstrating subtle signs and symptoms; Implement consensus recommendations on the age-specific management of patients with Rett syndrome; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of emerging pharmacologic treatment options to consider implementing these novel therapies when they become available.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC 1:00:17
1:00:17
Play Later
Play Later
Lists
Like
Liked1:00:17
Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 David Staskin, MD - Controlling the Urgency Emergency, Restoring QOL: Safe and Effective Management of Overactive Bladder 29:35
29:35
Play Later
Play Later
Lists
Like
Liked29:35
Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 R. Sharon Chinthrajah, MD - IgE-Mediated Food Allergies: Improving Patient Quality of Life Through a Multidisciplinary Approach as a New Era of Treatment Dawns 33:02
33:02
Play Later
Play Later
Lists
Like
Liked33:02
Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sarah S. Chisolm, MD - Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care? 1:02:57
1:02:57
Play Later
Play Later
Lists
Like
Liked1:02:57
Go online to PeerView.com/ZXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) causes intensely itchy, painful bumps leading to scratching, bleeding, and thickening of the nodules, with negative effects on sleep, mental health, activities of daily living, social interaction, and quality of life. There are no approved treatments for PN, but several agents in late-stage clinical trials offer hope to patients with this burdensome disease. At a recent live PeerView MasterClass & Practicum, a panel of PN experts offered evidence-based, practical guidance on current diagnostic and treatment strategies and the latest clinical data regarding novel therapies. The discussion was enhanced by a 3D animation depicting PN pathophysiology and patient videos providing perspectives on the burdens of disease and treatment experience. Upon completion of this activity, participants should be better able to: Recognize how the signs and symptoms of prurigo nodularis (PN) impact patient quality of life; Explain how type 2 inflammation may play a role in the pathophysiology of PN; Describe current and emerging treatment options for PN in the context of mechanism of action, efficacy, and safety; and Develop individualized treatment plans for PN using currently available therapies and appropriately incorporating novel agents as they become available.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Cedric "Jamie" Rutland, MD - Addressing the Underlying Inflammation of Non–Cystic Fibrosis Bronchiectasis: Exploring Novel Treatments to Change Disease Course for Patients and Improve Quality of Life 28:12
28:12
Play Later
Play Later
Lists
Like
Liked28:12
Go online to PeerView.com/HTX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non-cystic fibrosis bronchiectasis is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. The disease manifests as chronic airway inflammation, impaired mucociliary clearance, and structural lung damage leading to recurrent infections, persistent cough, sputum production, and exacerbations. The prevalence of bronchiectasis has been on the rise. Evolving insights into the pathophysiology of bronchiectasis have led to the development of novel and emerging agents to address the underlying inflammation, with the potential of changing the treatment landscape. In this animated activity, you will learn how to optimize clinical decision-making for patients with non-cystic fibrosis bronchiectasis that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations to the diagnosis and treatment of patients with bronchiectasis, with a goal of identifying and treating underlying causes; Describe the underlying mechanisms believed to contribute to inflammation in non–cystic fibrosis bronchiectasis and their correlation to emerging treatments; Assess recent clinical trial data concerning efficacy and safety of novel and emerging treatment options for non–cystic fibrosis bronchiectasis; and Develop strategies for preventing and treating exacerbations (eg, airway clearance, use of antibiotics, corticosteroids) in patients with non–cystic fibrosis bronchiectasis based on the latest expert recommendations using a personalized approach.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Wanda Phipatanakul, MD, MS - Controlling Moderate to Severe Asthma Across the Lifespan in an Ever-Evolving Treatment Landscape: How Much Do You Know? 31:51
31:51
Play Later
Play Later
Lists
Like
Liked31:51
Go online to PeerView.com/QYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Asthma is a common, chronic, and heterogeneous disease that can result in poor quality of life and severe, life-threatening exacerbations despite standard controller therapy. Type 2 inflammation, mediated by cytokines such as IL-4, IL-5, and IL-13, occurs in about 50% of patients with asthma and has emerged as a unifying feature of classically defined allergic diseases and a range of other inflammatory diseases. In this activity, an expert explains the advances in understanding of the pathogenesis of asthma and the targeted treatments that have been developed as a result. You will hear expert insights into the use of available and emerging biologic therapies, including how to identify children and adults who may be eligible for these therapies. Upon completion of this activity, participants should be better able to: Identify patients who would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis; Incorporate evidence-based and guideline-directed treatment for pediatric and adult patients with moderate to severe asthma into customized management plans; and Use techniques to educate and communicate with patients and caregivers to engage them in care and improve adherence to individualized treatment plans.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Robert Sidbury, MD, MPH - Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis? 39:59
39:59
Play Later
Play Later
Lists
Like
Liked39:59
Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Aditya Bardia, MD, MPH - Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care 50:07
50:07
Play Later
Play Later
Lists
Like
Liked50:07
Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individualized management plans for patients with breast cancer that incorporate TROP2-targeting therapies using the latest clinical evidence and current practice guidelines to inform daily practice; and Apply a team-based approach to care that incorporates shared decision-making and patient counseling/education and leverages effective interprofessional collaboration and care coordination.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to… 34:48
34:48
Play Later
Play Later
Lists
Like
Liked34:48
Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Rupa R. Patel, MD, MPH, DTM&H - A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care 37:20
37:20
Play Later
Play Later
Lists
Like
Liked37:20
Go online to PeerView.com/AHC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures. Upon completion of this activity, participants should be better able to: Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19; Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures; and Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - New Therapies, New Hope: Evolving Strategies for Improving Outcomes and Quality of Life in Patients With Hypertrophic Cardiomyopathy 49:01
49:01
Play Later
Play Later
Lists
Like
Liked49:01
Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Domenica M. Rubino, MD - Getting Ahead of the Curve: Identifying and Managing Obesity in Primary Care 1:01:02
1:01:02
Play Later
Play Later
Lists
Like
Liked1:01:02
Go online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and addressing obesity as a chronic disease, including effects on appetite regulation, metabolic adaptation, and preventing/managing obesity-related complications, adjunct to lifestyle modification; Assess current guidance and available long-term efficacy and safety data for current and emerging weight-loss pharmacotherapies in people with or at risk for obesity; and Incorporate weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Richard Beaser, MD - A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes 1:25:30
1:25:30
Play Later
Play Later
Lists
Like
Liked1:25:30
Go online to PeerView.com/TFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Who holds the key that can unlock the door to vision-saving treatments for patients with diabetic retinopathy (DR) and diabetic macular edema (DME)? The answer is primary diabetes care professionals: Timely screening and referral to eye care professionals can make a real difference between good vision and blindness for patients with DR/DME. The diagnosis and treatment of DR/DME has advanced greatly in the last decade. What can endocrinologists, diabetologists, and primary diabetes care professionals tell their patients to expect when they meet with a retina specialist? In this activity, based on a recent PeerView Live event, leading experts take a well-rounded look at the screening, diagnosis, and referral for treatment of individuals with DR/DME, including a practical review of the evidence for current and emerging treatment options. The experts discuss patient cases with varying degrees of urgency for referral, offering a glimpse into how decisions made by primary diabetes care professionals can speed access to the appropriate eye care professional to directly benefit and improve outcomes for patients with, or at risk for, DR/DME. Upon completion of this activity, participants should be better able to: Describe the roles of diabetes specialists in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referrals to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Leonard H. Calabrese, DO - Recognition and Management of Axial Spondyloarthritis: Best Practices for Family Medicine Physicians 11:13
11:13
Play Later
Play Later
Lists
Like
Liked11:13
Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Bruce Cree, MD, PhD, MAS - Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy 1:00:31
1:00:31
Play Later
Play Later
Lists
Like
Liked1:00:31
Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know 1:02:57
1:02:57
Play Later
Play Later
Lists
Like
Liked1:02:57
Go online to PeerView.com/REA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA. The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice. Upon completion of this activity, participants should be better able to: Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities; Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets; Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile; and Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Joan T. Merrill, MD - New Directions in Kinase Inhibition in Systemic Lupus Erythematosus: Emerging Evidence From Copenhagen 29:07
29:07
Play Later
Play Later
Lists
Like
Liked29:07
Go online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the care spectrum. In this expert-driven activity, you will hear the latest clinical evidence presented during the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress in Copenhagen, Denmark, with regard to the current treatment options for SLE and the potential for TYK2 inhibitors to change SLE management. Upon completion of this activity, participants should be better able to: Recognize the burden of SLE and the impact of delayed or suboptimal treatment on patient outcomes; Describe the mechanistic rationale and recent safety and efficacy data supporting a role for targeting TYK2 and BTK as potential therapeutic approaches in SLE; and Identify SLE patients who might benefit from emerging TYK2 and BTK inhibition strategies through clinical trial enrollment and recognizing potential implications for a future treatment paradigm.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice 25:36
25:36
Play Later
Play Later
Lists
Like
Liked25:36
Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Shmuel Shoham, MD - Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge 48:20
48:20
Play Later
Play Later
Lists
Like
Liked48:20
Go online to PeerView.com/EWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Solid organ transplant recipients may be at increased risk for COVID-19 because they are immunosuppressed and less likely to mount effective immune responses to vaccination. In this educational symposium based on a live event, a panel of expert faculty address the identification of transplant patients who would likely derive benefit from anti-SARS-CoV-2 monoclonal antibodies (mAbs) and strategies that can be used to overcome barriers to COVID-19 pre-exposure prophylaxis access. In addition, they provide guidance on mAb qualities and clinical profiles and shared decision-making strategies to customize mAb pre-exposure prophylaxis at the point of care for transplant recipients needing protection against COVID-19. After participating in this activity, the learner will demonstrate the ability to: Identify post-transplant patients who would likely derive benefit from pre-exposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies (mAbs); Use strategies to overcome barriers to COVID-19 pre-exposure prophylaxis access for post-transplant patients; and Incorporate evidence-based recommendations and guidelines, mAb qualities and clinical profiles, and shared decision-making into strategies to customize mAb pre-exposure prophylaxis at point of care for post-transplant patients needing protection against COVID-19.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 David Alain Wohl, MD - Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities 34:40
34:40
Play Later
Play Later
Lists
Like
Liked34:40
Go online to PeerView.com/BED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women. Upon completion of this activity, participants should be better able to: Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women; Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women; and Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Toni K. Choueiri, MD - Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care 1:27:05
1:27:05
Play Later
Play Later
Lists
Like
Liked1:27:05
Go online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC as well. Designed to bridge the gap between theory and practice, this CME/MOC-certified educational activity, in partnership with KCCure, features expert guidance on how oncologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Upon completion of this activity, participants should be better able to: Assess the therapeutic roles of and key efficacy and safety evidence on novel and emerging systemic therapy strategies for patients with localized or advanced/metastatic RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, guideline recommendations, and patient-, disease- and treatment-specific factors; Integrate evidence-based strategies and best practices to recognize, mitigate and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Reynold A. Panettieri, Jr., MD - The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins 31:17
31:17
Play Later
Play Later
Lists
Like
Liked31:17
Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lisa H. Lancaster, MD - The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management 33:53
33:53
Play Later
Play Later
Lists
Like
Liked33:53
Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies 36:54
36:54
Play Later
Play Later
Lists
Like
Liked36:54
Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer’s disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting 1:03:14
1:03:14
Play Later
Play Later
Lists
Like
Liked1:03:14
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Petros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice… 1:26:22
1:26:22
Play Later
Play Later
Lists
Like
Liked1:26:22
Go online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Summarize the current roles, mechanisms of action, and key evidence pertaining to novel systemic therapies for patients with localized or metastatic bladder cancer, such as immunotherapies, small molecule targeted therapies, and antibody-drug conjugates, among others, Plan personalized treatment algorithms for patients with localized or metastatic urothelial cancer that incorporate novel and emerging therapies, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Implement evidence-based strategies and expert recommendations to prevent, mitigate and/or manage treatment-related adverse events that may occur among patients receiving novel systemic therapies for bladder cancer.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Fine-Tuning the JAK/STAT Pathway in Psoriasis: Safely Targeting the Underlying Mechanisms of Disease With TYK2 Inhibition 1:01:45
1:01:45
Play Later
Play Later
Lists
Like
Liked1:01:45
Go online to PeerView.com/CCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss the role of the JAK/STAT pathway in psoriasis, as well as treatment with novel kinase inhibitors for the management of patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe and differentiate targeting of the TYK2, JAK1, JAK2, and JAK3 kinases and the correlation to emerging therapies for the treatment of moderate to severe psoriasis, Summarize recent efficacy and safety data for current and emerging therapies for the treatment of moderate to severe psoriasis, Recommend treatment for patients with moderate to severe psoriasis according to the latest guidelines and clinical evidence, particularly as emerging therapies become available.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the… 1:21:18
1:21:18
Play Later
Play Later
Lists
Like
Liked1:21:18
Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Liana G. Apostolova, MS, MD, FAAN - Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild… 1:44:57
1:44:57
Play Later
Play Later
Lists
Like
Liked1:44:57
Go online to PeerView.com/JYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this activity, based on a live symposium held at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases in Barcelona, Spain, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emerging biomarkers that can aid in the early diagnosis of AD. They will also explore the mechanisms of action, efficacy, and safety data for promising disease-modifying therapies in development for the treatment of AD. Using patient case examples to frame the discussion, the expert faculty panel will provide practical guidance on how clinicians can effectively and safely integrate new diagnostic tools and disease-modifying therapies into clinical practice. Upon completion of this activity, participants should be better able to: Describe the rationale for identifying patients at risk for Alzheimer’s disease (AD) early in the disease course, Utilize validated neuroimaging techniques and molecular biomarkers to make early and accurate neuropathological diagnoses of AD, Select appropriate AD patients who may benefit from novel disease-modifying therapies based on an understanding of their respective mechanisms of action, efficacy, and safety profiles.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes 36:02
36:02
Play Later
Play Later
Lists
Like
Liked36:02
Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Brett King, MD, PhD - Addressing Healthcare Disparities and Optimizing Patient Outcomes in Atopic Dermatitis and Alopecia Areata: Expert Insight on How to Improve Access and Quality of Care 1:25:34
1:25:34
Play Later
Play Later
Lists
Like
Liked1:25:34
Go online to PeerView.com/TJZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss strategies to optimize patient outcomes in atopic dermatitis and alopecia areata. Upon completion of this activity, participants should be better able to: Appropriately diagnose atopic dermatitis (AD) and alopecia areata (AA) and assess severity to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities, Describe current and emerging treatments for AD and AA in the context of mechanism of action, efficacy and safety profile, dosage and administration, and other factors relevant to clinical use, Utilize available resources to identify and overcome racial and ethnic health disparities in the management of AD and AA and ultimately improve health outcomes in under-represented populations.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anthony Martinez, MD, AAHIVS, FAASLD - Sharing the Cure: Best Practices for Primary Care Providers to Improve HCV Prevention, Care, and Treatment 28:29
28:29
Play Later
Play Later
Lists
Like
Liked28:29
Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sarina Elmariah, MD, PhD, MPH - Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options 42:27
42:27
Play Later
Play Later
Lists
Like
Liked42:27
Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they care. By providing practical guidance on how to effectively integrate the latest evidence and expert recommendations into real-world clinical scenarios, this activity provides participating clinicians with the necessary tools to effectively navigate the rapidly changing landscape for PN. Additionally, patient videos are utilized throughout to convey key information regarding the burden of PN and optimal management strategies. Upon completion of this activity, participants should be better able to: Discuss the impact on quality of life and economic implications of prurigo nodularis (PN), Describe the pathophysiology of PN as it relates to clinically relevant disease mechanisms and novel therapeutic targets, Evaluate emerging treatment options for PN in the context of mechanism of action, efficacy, and safety, Treat PN in accordance with current evidence and expert recommendations, recognizing that an effective treatment approach should be based on clinical judgment and tailored to the individual needs of the patient.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Professor Andrew Menzies-Gow - Tackling the Challenge of Treating Severe Asthma: Taking Aim at the Airway Epithelium 32:12
32:12
Play Later
Play Later
Lists
Like
Liked32:12
Go online to PeerView.com/MRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of the airway epithelium in severe asthma treatment. Upon completion of this activity, participants should be better able to: Apply the latest pathophysiologic insights into the role of epithelial alarmins in the development of inflammation and structural changes in the airways to the treatment of patients with severe asthma, Discuss the clinical implications of biologic treatment that is not limited by phenotype or biomarker for patients with severe asthma whose disease remains uncontrolled despite standard treatment, Identify patients with severe asthma who may be eligible for treatment with novel biologic therapies that target epithelial alarmins.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Joseph Diaz, MD- Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life 52:52
52:52
Play Later
Play Later
Lists
Like
Liked52:52
Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient’s clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Joe R. Anderson, PharmD, PhC - Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care 1:01:18
1:01:18
Play Later
Play Later
Lists
Like
Liked1:01:18
Go online to PeerView.com/KMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes. Upon completion of this activity, participants should be better able to: Identify ways that pharmacists can work collaboratively with other clinical colleagues to bridge the gap between patients and healthcare team professionals to improve AF screening, diagnosis, and treatment, Screen individuals who are at risk for stroke due to undiagnosed AF and refer them for further evaluation and treatment, as appropriate, Collaborate with clinical colleagues to ensure that evidence-based, guideline-recommended treatment is discussed and offered to patients with AF to reduce the risk of stroke, Educate patients with AF about the heightened risk of stroke and the importance of anticoagulation therapy.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in… 57:16
57:16
Play Later
Play Later
Lists
Like
Liked57:16
Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Elizabeth Eaman, MD - Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations 1:06:47
1:06:47
Play Later
Play Later
Lists
Like
Liked1:06:47
Go online to PeerView.com/YDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It is estimated that there are about 1 million adults in the United States who identify as transgender, and this number may be higher depending on the surveys used, the questions asked, and the diversity of subcultures within the transgender community. Although being transgender is not in itself a medical condition, transgender individuals have unique healthcare needs and face barriers to screening and preventive care, particularly with cancer screening. Consequently, these patients may receive lower quality medical care than the general population as a result of stigma, discrimination, and providers’ lack of knowledge about gender identity. Additionally, transgender patients may only seek medical care as part of gender affirmation and avoid primary care health concerns, including screenings. This activity, based on a recent live web broadcast, will focus on improving cancer prevention and early detection strategies in the transgender community, as well as enhancing the knowledge and competence of interdisciplinary and interprofessional healthcare providers to appropriately deliver culturally competent care. An interdisciplinary panel of recognized clinical experts will offer learners tactics to improve disease prevention in transgender patients, while the patient advocate will provide the transgender patient perspective throughout the program. Upon completion of this activity, participants should be better able to: Recognize that transgender individuals may be disproportionately at increased risk for contracting HIV and those living with HIV have an increased risk of several types of cancers, Properly screen for and identify cancer in a timely manner to prevent advanced disease in the transgender community, Develop individualized preventive care plans for transgender patients consistent with the patient's current anatomical structure, Provide affirming, inclusive, and culturally humble care to transgender patients to facilitate adherence to clinical recommendations and engagement in care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer 28:20
28:20
Play Later
Play Later
Lists
Like
Liked28:20
Go online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Implement appropriate strategies for biomarker testing and integration of novel immunotherapy options into personalized management plans for patients with recurrent or advanced endometrial cancer, in alignment with the latest clinical evidence, approved indications, and guideline recommendations, Employ proactive, collaborative strategies to mitigate and manage immune-related adverse events in patients receiving immune-based therapies for recurrent and advanced endometrial cancers, Apply multidisciplinary, interprofessional, and patient-centric practices and tools that can realistically serve to mitigate disparities in healthcare service delivery and cancer-related outcomes for patients with endometrial cancer.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Michael E. Wechsler, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients With Uncontrolled, Moderate to Severe Asthma: Comparing Approaches With Experts Around the World 1:02:56
1:02:56
Play Later
Play Later
Lists
Like
Liked1:02:56
Go online to PeerView.com/VMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence. Upon completion of this activity, participants should be better able to: Assess the severity of asthma in pediatric and adult patients according to evidence-based practice guidelines, Identify patients that would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis, Select treatment for pediatric and adult patients with uncontrolled, moderate to severe asthma according to current evidence and guidelines, Use techniques to educate and communicate more effectively with patients and caregivers to better engage them in their care, and improve adherence to individualized treatment plans.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anjay Rastogi, MD - Making the Case for Preventing and Managing Nephropathy in Patients With Fabry Disease 35:16
35:16
Play Later
Play Later
Lists
Like
Liked35:16
Go online to PeerView.com/GPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses the prevention and management of nephropathy in patients with Fabry disease. Upon completion of this activity, participants should be better able to: Employ evidence-based tools and strategies to identify patients with FD and prevent nephropathy in a timely manner, Assess safety and efficacy of current and emerging treatments for patients with FD, Apply individualized treatment for patients with FD with an emphasis on preventing nephropathy.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity 1:05:17
1:05:17
Play Later
Play Later
Lists
Like
Liked1:05:17
Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Milind Desai, MD, MBA - New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy: Analysis From Washington, DC 29:16
29:16
Play Later
Play Later
Lists
Like
Liked29:16
Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting 29:36
29:36
Play Later
Play Later
Lists
Like
Liked29:36
Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer 34:41
34:41
Play Later
Play Later
Lists
Like
Liked34:41
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anita H. Clayton, MD - Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm 36:08
36:08
Play Later
Play Later
Lists
Like
Liked36:08
Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Kristina M. Deligiannidis, MD - Applying Evidence to Practice in Postpartum Depression: Expert Guidance on Integrating Therapeutic Innovations and Shared Decision-Making Strategies to Optimize… 1:00:56
1:00:56
Play Later
Play Later
Lists
Like
Liked1:00:56
Go online to PeerView.com/HYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in women’s behavioral health shares a downloadable tool kit created for OB/GYNs and other clinicians to facilitate the screening, diagnosis, and treatment of postpartum depression (PPD) and to provide guidance on the use of shared decision-making strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Utilize validated screening tools and current clinical guidelines to facilitate the early diagnosis of PPD, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for PPD, Develop individualized treatment protocols for patients with PPD that incorporate evidence-based care and shared decision-making.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Herbert L. Bonkovsky, MD - Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It? 38:21
38:21
Play Later
Play Later
Lists
Like
Liked38:21
Go online to PeerView.com/DQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in acute hepatic porphyria (AHP) reviews the diagnostic criteria for AHP and examines current treatment options. Upon completion of this activity, participants should be better able to: Apply laboratory and diagnostic assessments to confirm suspicion of AHP, Recognize disease burdens that patients with AHP frequently experience (eg, impact on overall health, quality of life, daily activities), Employ evidence-based treatment regimens that include siRNA therapy, as appropriate, to improve outcomes, minimize disease impact, and reduce the burdens of disease in patients with AHP.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention 1:03:13
1:03:13
Play Later
Play Later
Lists
Like
Liked1:03:13
Go online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an interprofessional manner to identify patients in primary care at risk for VTE, Compare the efficacy and safety profile and dosing regimens of available treatment options for VTE, Implement the most up-to-date evidence-based guidelines in the management of VTE to determine an individually appropriate treatment strategy for each patient, Explain the indications and rationale for standard vs extended treatment for the secondary prevention of VTE, Educate patients on the heightened risk of VTE recurrence, and the importance of treatment adherence.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Julie Parsons, MD - Breakthroughs in Spinal Muscular Atrophy: Managing the Life-Changing Impact of Gene Replacement Therapy 33:45
33:45
Play Later
Play Later
Lists
Like
Liked33:45
Go online to PeerView.com/FFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the life-changing impact of gene replacement therapy in spinal muscular atrophy. Upon completion of this CE activity, participants will be able to: Recognize the underlying genetics and pathophysiology of spinal muscular atrophy, Identify appropriate patients with SMA for treatment with gene replacement therapy, Counsel patients, families, and caregivers about gene replacement therapy for SMA, including eligibility, potential benefits and risks, and anticipatory guidance regarding prognosis, the need for ongoing care, and long-term safety monitoring, Employ post-treatment multidisciplinary management plans for patients who have been treated for SMA with gene replacement therapy.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Carla M. Nester, MD, MSA, FASN - Hope Is on the Horizon: The Clinical Potential of Emerging Disease-Modifying Therapies for Managing Complement 3 Glomerulopathy 19:55
19:55
Play Later
Play Later
Lists
Like
Liked19:55
Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Cindy Neunert, MD, MSCS - Modern Management of ITP: Thinking Beyond the Conventional Therapies 33:04
33:04
Play Later
Play Later
Lists
Like
Liked33:04
Go online to PeerView.com/GAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management. Upon completion of this CE activity, participants will be able to: Discuss current challenges, unmet needs, and newer developments in ITP including the importance of differential diagnosis, testing, and guideline recommendations in treatment decision-making, Analyze safety, efficacy, evidence, and mechanism of action of BTKis and other emerging agents to improve quality of life and invoke long-term, off-treatment remissions, Develop personalized treatment plans for front-line and second-line therapies based on patient- and disease-specific factors to improve patient outcomes in ITP.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 J. Fernando Arevalo - Seeing Eye to Eye: Improving Outcomes Among Rural Spanish-Speaking Latinx Patients With Diabetic Retinopathy or Diabetic Macular Edema 50:55
50:55
Play Later
Play Later
Lists
Like
Liked50:55
Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Petros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions 1:28:17
1:28:17
Play Later
Play Later
Lists
Like
Liked1:28:17
Go online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts will pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity highlights strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this CE activity, participants will be able to: Incorporate the latest clinical evidence, describe the current therapeutic roles and mechanistic rationales of novel systemic therapies, including immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates, across bladder cancer settings and patient populations (eg, localized or metastatic), Develop personalized treatment plans for patients with localized or metastatic bladder cancer that incorporate novel agents, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Employ evidence-based, collaborative strategies to mitigate and manage treatment-related AEs in patients receiving novel systemic therapies for bladder cancer.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs 32:30
32:30
Play Later
Play Later
Lists
Like
Liked32:30
Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Amit Bar-Or, MD, FRCPC / Daniel S. Reich, MD, PhD - Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now 52:37
52:37
Play Later
Play Later
Lists
Like
Liked52:37
Go online to PeerView.com/TCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in MS discuss the rationale, evidence, and practical potential for BTK inhibitors in patient-centered MS care. Upon completion of this CE activity, participants will be able to: Describe the rationale for inhibiting Bruton’s tyrosine kinase (BTK) to treat multiple sclerosis (MS), Evaluate current evidence related to the efficacy and safety of BTK inhibitors in the treatment of MS, Identify patients who could benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults 1:21:22
1:21:22
Play Later
Play Later
Lists
Like
Liked1:21:22
Go online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion of treatment options has also presented dilemmas for those trying to choose the right treatment for the right patient. For instance, next-generation anti-androgen agents have proven efficacious in early stages of prostate cancer, while approvals of poly (ADP-ribose) polymerase (PARP) inhibitors are available in later-line metastatic castration-resistant prostate cancer (mCRPC). Combination approaches, under investigation across various stages of prostate cancer, further highlight the expansive opportunities for treatment personalization across the disease continuum. Given this new wealth of options, how do clinicians determine the best treatment course for each patient? Join PeerView and the Prostate Conditions Education Council for an expert-led event designed to answer important questions on prostate cancer treatment in the modern era. Combining insight on relevant data from important trials with practical guidance on using guideline-recommended strategies in clinical practice, this event will help clinicians provide optimal personalized care informed by relevant patient-, tumor-, and treatment-related factors and address AEs related to newer therapies and combinations. Upon completion of this CE activity, participants will be able to: Apply current guideline recommendations for germline and tumor testing for clinically relevant biomarkers in patients with prostate cancer, Integrate novel treatment regimens into the management of patients with advanced prostate cancer, based on recent evidence, genetic/molecular features, current guideline recommendations, and individual patient needs and preferences, Employ evidence- and team-based approaches to proactively mitigate and manage treatment-related AEs that may arise in patients receiving novel therapies and combinations for advanced prostate cancer.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Sam Cheng, MD / Angela Pham, MD - Short Bowel Syndrome IMPACT Initiative: An Initiative to Individualize Treatment and Improve the Pediatric to Adult Healthcare Transition 1:10:38
1:10:38
Play Later
Play Later
Lists
Like
Liked1:10:38
Go online to PeerView.com/SWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Rohit Loomba, MD, MHSc - Test Your Knowledge of What’s Now and What’s Next: Modification of Metabolic Risk Factors to Improve Liver-Related and Cardiovascular‐Related Outcomes in NASH 26:43
26:43
Play Later
Play Later
Lists
Like
Liked26:43
Go online to PeerView.com/FCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology provides practical guidance across the spectrum of care from screening and diagnosis to management of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the epidemiology and disease burden of NAFLD/NASH, Describe the relationship between NAFLD/NASH and cardiovascular disease, Assess current and emerging treatments for NASH in the context of mechanism of action (eg, ability to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression) and current clinical evidence (eg, impact on fibrosis and cardiovascular risk; safety)…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Tammie L.S. Benzinger - The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Management: Is Radiology Prepared for New Challenges? 32:45
32:45
Play Later
Play Later
Lists
Like
Liked32:45
Go online to PeerView.com/KZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A multidisciplinary panel of experts discuss the expanding role of neuroimaging in the diagnosis and management of Alzheimer’s disease. Upon completion of this CE activity, participants will be able to: Assess the relative utility of the structural, functional, and molecular neuroimaging techniques used in AD diagnosis and management, Implement an evidence-based, guideline-directed approach to using neuroimaging to assess amyloid burden when confirming a diagnosis of AD or determining patient eligibility for use of amyloid-lowering therapy, Apply validated neuroimaging techniques and biomarkers to monitor for treatment response, disease progression, and ARIA or other adverse events in patients being treated for AD, Employ a patient-centered, multidisciplinary approach to patient care in AD…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 William D. Tap, MD - Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options 18:47
18:47
Play Later
Play Later
Lists
Like
Liked18:47
Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Alan "Tony" Amberg - Addressing Unmet Needs in the Management of Schizophrenia and Bipolar Disorder: New and Emerging Therapeutic Options to Enhance Treatment and Maximize Patient Outcomes 29:11
29:11
Play Later
Play Later
Lists
Like
Liked29:11
Go online to PeerView.com/JUV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Christian B. Ramers, MD, MPH, AAHIVS - A Closer Look at Telehealth for HIV: Best Practices for Patient Management in a Unique Era of Care 30:58
30:58
Play Later
Play Later
Lists
Like
Liked30:58
Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Carlos M. de Castro, MD - Upstream and Downstream Targeting of the Complement Pathway to Manage PNH: Current and Emerging Inhibitors 19:08
19:08
Play Later
Play Later
Lists
Like
Liked19:08
Go online to PeerView.com/YQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology-oncology provides an overview of paroxysmal nocturnal hemoglobinuria (PNH) and discusses current and emerging treatment options for managing PNH. Upon completion of this CE activity, participants will be able to: Discuss the complement pathway and its mechanistic relationship to paroxysmal nocturnal hemoglobinuria (PNH), Summarize efficacy and safety data surrounding complement pathway inhibitors, including factor B inhibitors, to treat PNH, Manage the unique adverse events associated with complement pathway inhibitors for PNH.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Anita H. Clayton, MD - Recent Advances and Novel Options in Depression: Reviewing the Evidence for GABA-Modulating Neuroactive Steroids for Major Depressive Disorder 31:49
31:49
Play Later
Play Later
Lists
Like
Liked31:49
Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 George L. Bakris, MD / Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF - Advancing the Standard of Care for Patients with Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice 1:23:58
1:23:58
Play Later
Play Later
Lists
Like
Liked1:23:58
Go online to PeerView.com/YVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hyperkalemia is a potentially life-threatening condition caused by the inability of the kidneys to excrete potassium sufficiently. Excessive potassium levels can lead to cardiac arrhythmias and sudden cardiac death. Hyperkalemia is often encountered in hospitalized patients and frequently recurs after discharge. The problem is further complicated by the fact that guideline-directed medical therapies frequently used to reduce cardiorenal risks in patients with heart failure (HF) or chronic kidney disease (CKD) can increase the risk of hyperkalemia. Newer potassium binders may allow these patients to better tolerate guideline-directed therapies, as well as reduce the risk of hyperkalemia recurrence. Interprofessional models of care, such as those involving the pharmacist in transition-of-care interventions, have also been shown to improve patient outcomes. In this activity, based on a recent live web broadcast, an interprofessional expert panel examines the diagnostic thresholds for hyperkalemia, the factors that contribute to its risk in patients with HF, CKD, or diabetes, and the associations between hyperkalemia and poor patient outcomes. The experts also explore the latest evidence for modern potassium binders, share evidence-based strategies for integrating these agents into patient-centered treatment plans, and consider how interprofessional approaches to care can improve patient outcomes and potentially reduce readmission rates. Upon completion of this CE activity, participants will be able to: Recognize thresholds for mild, moderate, and severe hyperkalemia and their implications for recurrent hospital admissions and mortality, Describe the burden of hyperkalemia in patients with HF and CKD and its association with renin-angiotensin-aldosterone system (RAAS) inhibitors, Differentiate agents for managing hyperkalemia according to their mechanisms of action, indications, and pharmacologic characteristics, Apply evidence-based strategies to manage hyperkalemia, optimize care transitions, and potentially reduce hyperkalemia-related hospital readmissions in patients with HF or CKD.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Bradley S. Miller, MD, PhD - Advances in Pediatric Growth Hormone Therapy: Visualizing the Impact on Individualized Care 35:40
35:40
Play Later
Play Later
Lists
Like
Liked35:40
Go online to PeerView.com/VUG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric growth hormone deficiency (pGHD) discusses the latest advances in treatment and patient-centered approaches to care. Upon completion of this activity, participants should be better able to: Identify appropriate pediatric candidates for growth hormone (GH) therapy based on approved indications, current recommendations, and relevant diagnostic test results, Evaluate evidence regarding the clinical characteristics (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) of available and emerging GH therapies, Individualize pediatric GH therapy to include efforts that address patient needs and preferences, such as personalized dosing, therapeutic monitoring, and assistance with care transitions.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management 1:25:23
1:25:23
Play Later
Play Later
Lists
Like
Liked1:25:23
Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Robert Dreicer, MD, MS, MACP, FASCO/Pedro C. Barata, MD, MSc - Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer 57:27
57:27
Play Later
Play Later
Lists
Like
Liked57:27
Go online to PeerView.com/TGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the multidisciplinary relationship between urologic oncologists and advanced practice clinicians in the management of patients with prostate cancer has become increasingly more important in providing the best patient care. During this video, an expert panel highlights how a multidisciplinary team can use the latest clinical evidence, treatment guidelines, and expert consensus recommendations to improve care for patients with prostate cancer and gives practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. The experts also provide meaningful guidance to assist clinicians in optimizing treatment planning based on a modern understanding of prostate cancer biology, best treatment practices, and the expanding opportunities for treatment personalization across the disease continuum. Upon completion of this CE activity, participants will be able to: Implement guideline recommendations related to genetic testing when managing patients with prostate cancer, Apply current evidence about available and emerging anti-androgen and non-hormonal agents when deciding on treatment for prostate cancer, Integrate appropriate anti-androgen and non-hormonal strategies into treatment plans for patients with prostate cancer.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lenard A. Adler, MD / Oren Mason, MD - Overcoming Challenges in the Recognition and Management of Adult ADHD in Primary Care: Optimizing Outcomes to Reduce Disease Burden and Improve Quality of Life 1:00:58
1:00:58
Play Later
Play Later
Lists
Like
Liked1:00:58
Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient’s ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Emma Guttman-Yassky, MD, PhD - Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis 1:00:58
1:00:58
Play Later
Play Later
Lists
Like
Liked1:00:58
Go online to PeerView.com/AYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts will review the presentation and diagnosis of AD and discuss the current evidence and guidelines for treatment selection for pediatric and adult patients. The faculty will also offer their thoughts on engaging with patients to provide personalized care and improved outcomes. Learn from the data and the experts in this informative, engaging discussion. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD), Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines, Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 David Malebranche, MD, MPH - Parallel Perspectives: A Unique Look at HIV Treatment Decisions From the Provider and the Patient 1:08:24
1:08:24
Play Later
Play Later
Lists
Like
Liked1:08:24
Go online to PeerView.com/ZWH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite a widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, there has been unequal progress with increasing access to treatment and reducing the number of new HIV infections and AIDS-related deaths, resulting in several vulnerable populations being left behind. Stigma and discrimination, together with other social inequalities and exclusion, are proving to be key barriers in battling this epidemic. In this activity, based on a recent live web broadcast, provider and patient perspectives on overcoming barriers to modern HIV treatment strategies will be examined. Additionally, the engaging panel will discuss the importance of establishing strong patient–provider relationships and demonstrating an understanding of the unique challenges faced by each individual patient living with HIV. Upon completion of this CE activity, participants should be better able to: Apply updated evidence-based guidelines and recent clinical data when recommending initial antiretroviral therapy (ART) regimens and switch strategies for individual patients infected with HIV, Assess the potential impact of clinical trial data related to emerging therapeutic strategies for HIV, Effectively prevent or manage drug–drug interactions, adverse events, and other complications associated with HIV, ART, and comorbidities, Establish strong patient–provider relationships, and demonstrate an understanding of the unique challenges faced by each individual patient living with HIV, Develop strategies within the healthcare team to link people living with HIV to essential HIV care, treatment, and support services.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Steven E. Carsons, MD - Addressing Unmet Needs in the Treatment of Primary Sjögren's Syndrome: Expert Insight on the Therapeutic Potential for CD40 Pathway Blockade 33:33
33:33
Play Later
Play Later
Lists
Like
Liked33:33
Go online to PeerView.com/FFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Sjögren’s Syndrome reviews current concepts in the pathophysiology of pSS, and discusses the obstacles faced in recent clinical trials and how new approaches may overcome these obstacles in the future. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with primary Sjögren’s Syndrome, Describe key pathways involved in the pathology of primary Sjögren’s Syndrome and implications for treatment, Evaluate recent clinical trial data related to emerging treatment options for primary Sjögren’s Syndrome, Identify patients who might derive benefit from novel therapeutic options for primary Sjögren’s Syndrome.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared? 59:03
59:03
Play Later
Play Later
Lists
Like
Liked59:03
Go online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestations. These experts provide practical guidance on strategies and techniques for diagnosing, staging, and managing patients who present with various cardiac irAEs. This virtual session will engage participants with opportunities to participate in consultative assessments of real-world patient cases, including contributing to key aspects of diagnostic decision-making and deliberation of optimal strategies for collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Summarize the prevalence, biologic mechanisms, burden, and consequences of the development of cardiac immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Utilize algorithms and practical tools based on the latest clinical evidence and recommendations for identification, diagnosis/differential diagnosis, treatment, and management of cardiac irAEs, Integrate shared decision-making, team-based approaches, and telemedicine to facilitate multidisciplinary and interprofessional collaboration and care coordination and improve clinician-patient communication and patient outcomes.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Domenica M. Rubino, MD & Donna H. Ryan, MD, FTOS -Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management 57:41
57:41
Play Later
Play Later
Lists
Like
Liked57:41
Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatment plans in order to optimize health outcomes and promote long-term weight loss. Upon completion of this CE activity, participants will be able to: Recognize the role of weight-loss pharmacotherapy used adjunct to other treatment approaches for addressing obesity pathophysiology, including metabolic adaptation, Assess available evidence on current and emerging GLP-1–based weight-loss pharmacotherapies, including long-term efficacy and safety data, Incorporate GLP-1–based weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 R. Sharon Chinthrajah, MD - Fulfilling Unmet Treatment Needs for Patients With IgE-Mediated Food Allergies: An Animated Exploration of Emerging Targeted Therapy 25:29
25:29
Play Later
Play Later
Lists
Like
Liked25:29
Go online to PeerView.com/KHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies. Upon completion of this accredited CE activity, participants should be better able to: Discuss key limitations associated with current treatment approaches for managing food allergies, Differentiate the mechanisms of action of current and emerging treatments for IgE-mediated food allergies, Identify patients with IgE-mediated food allergies who would likely derive benefit from treatment with IgE-blocking therapies.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Donna E. Sweet, MD, AAHIVS, MACP - The HIV Prevention–Certified Provider Program: A Training and Certificate Program Designed to Improve Competencies and Expand the HIV Prevention Workforce 38:04
38:04
Play Later
Play Later
Lists
Like
Liked38:04
Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet’s personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider’s individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Benjamin M. Greenberg, MD, MHS & Professor Anthony Traboulsee, MD - Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach 49:02
49:02
Play Later
Play Later
Lists
Like
Liked49:02
Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Richard Elion, MD / Rupa R. Patel, MD, MPH, DTM&H - PrEP for All Ages: A Comprehensive Look at Employing HIV Prevention Strategies Across All Age Groups 38:55
38:55
Play Later
Play Later
Lists
Like
Liked38:55
Go online to PeerView.com/HNA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in infectious diseases discuss employing PrEP and HIV prevention strategies across all age groups. Upon completion of this activity, participants should be better able to: Describe the biologic principles and HIV prevention benefit of PrEP, Discuss clinical data to support PrEP use in different age groups (eg, youth, adults, and older adults), Develop strategies for the healthcare team to employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection across the lifespan, Facilitate access to PrEP among youth, adults, and individuals aged 50 and older.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Carl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic Retinopathy 1:34:09
1:34:09
Play Later
Play Later
Lists
Like
Liked1:34:09
Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Ikuo Hirano, MD - On the Cusp of a New Era in Treatment for Eosinophilic Esophagitis: Expert Insights on the Latest Advances in Targeted Therapy 19:27
19:27
Play Later
Play Later
Lists
Like
Liked19:27
Go online to PeerView.com/AZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in eosinophilic esophagitis discusses the latest research, data, and guidelines on novel and emerging targeted therapies. Upon completion of this CE activity, participants will be able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of eosinophilic esophagitis (EoE), Employ the latest clinical data, including evidence concerning novel and emerging targeted therapies, into treatment plans for the management of patients with EoE as they become available.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Bruce Cree, MD, PhD, MAS - Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis 56:27
56:27
Play Later
Play Later
Lists
Like
Liked56:27
Go online to PeerView.com/FUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, experts in neurology explore the mechanisms of action of S1PR modulators approved for the treatment of multiple sclerosis (MS), highlighting the similarities and differences among treatment options and reviewing the efficacy and safety data for these therapies and their potential effects on markers of treatment response or disease progression (eg, brain atrophy, neurofilament protein levels, cognitive test results). The burden, assessment, and management of cognitive impairment in MS, which occurs in over 50% of people with MS and can greatly affect patients’ functioning and quality of life, is also examined in this activity. The expert faculty also present and discuss patient case scenarios, through which they explore best practices in the care of patients with varied disease presentations and clinical contexts. Upon completion of this CE activity, participants will be able to: Describe the mechanisms of action for S1PR modulators approved for the treatment of MS in the context of disease pathophysiology, Recognize the therapeutic effects of S1PR modulators approved for the treatment of MS, including efficacy, safety, and tolerability, and the potential impact on emerging disease state markers (eg, brain atrophy, neurofilament protein, cognition), Use S1PR modulators appropriately, according to current recommendations and evidence, to meet treatment needs of individuals with MS.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan A. Bernstein, MD - Visualizing Progress in the Management of Chronic Spontaneous Urticaria: Harnessing the Clinical Potential of New and Novel Therapies to Address Unmet Patient Needs 22:10
22:10
Play Later
Play Later
Lists
Like
Liked22:10
Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan A. Bernstein, MD - Visualizing Progress in the Management of Chronic Spontaneous Urticaria: Harnessing the Clinical Potential of New and Novel Therapies to Address Unmet Patient Needs 26:47
26:47
Play Later
Play Later
Lists
Like
Liked26:47
Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Timothy Berger, MD - Changing the Game for Patients With Prurigo Nodularis: Best Practices to Achieve Treatment Goals and Improve Quality of Life 22:39
22:39
Play Later
Play Later
Lists
Like
Liked22:39
Go online to PeerView.com/AXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses best practices to achieve treatment goals and improve quality of life for patients with prurigo nodularis and a patient provides a firsthand account concerning the great impact the disease can have. Upon completion of this CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with prurigo nodularis (PN), Discuss advances in the underlying pathophysiology of PN that have led to the identification of new therapeutic targets, Describe the clinical profiles of emerging treatment options for PN, Develop treatment plans for PN that are tailored to the individual needs of each patient, considering clinical presentation, comorbidities, and response to prior therapies.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team 35:33
35:33
Play Later
Play Later
Lists
Like
Liked35:33
Go online to PeerView.com/AEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGCT presentations, and illustrate the nuances of multidisciplinary collaboration when managing patients with TGCT. Throughout, the panelists profile a modern management synthesis that combines surgery, physical therapy, and the use of targeted agents, including for patients for whom surgery alone is unlikely to be beneficial. Upon completion of this CE activity, participants will be able to: Interpret the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Utilize multidisciplinary management strategies for localized and diffuse TGCT that include collaboration between oncologists, orthopedic surgeons, advanced practice clinicians, and other relevant professionals, Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients for whom continued surgery is unlikely to produce clinical benefits, Manage safety and dosing considerations with targeted agents in the setting of TGCT.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis 25:18
25:18
Play Later
Play Later
Lists
Like
Liked25:18
Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Philip J. Mease, MD, MACR - Improving the Recognition and Effective Management of Axial Spondyloarthritis: Practical Guidance for the Primary Care Provider 33:33
33:33
Play Later
Play Later
Lists
Like
Liked33:33
Go online to PeerView.com/JTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses the recognition and management of axial spondyloarthritis (axSpA). Upon completion of this accredited CE activity, participants should be better able to: Describe axial spondyloarthritis (axSpA) pathophysiology and epidemiology and complications associated with diagnostic and treatment delays, Identify axSpA in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Assess efficacy and safety data related to novel treatment options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences, Recognize the importance of collaborating with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies 27:30
27:30
Play Later
Play Later
Lists
Like
Liked27:30
Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Daniel Jacoby, MD - Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology 51:27
51:27
Play Later
Play Later
Lists
Like
Liked51:27
Go online to PeerView.com/BQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live satellite symposium held at HFSA 2021, expert faculty review the evidence for current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM) using patient cases to illustrate the ways in which clinicians can adapt current practices and utilize shared decision-making to offer appropriate treatment options to patients with HCM. Upon completion of this activity, participants should be better able to: Recognize HCM’s pathophysiology and the associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Apply the latest recommendations and guidance for diagnosing, evaluating, and monitoring patients with HCM in a team-based manner, Evaluate current and emerging strategies for managing HCM in terms of efficacy, safety, and effects on burden of disease, Collaborate with patients to identify their individual goals and counsel them about the benefits and risks of testing and treatment.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics 1:19:32
1:19:32
Play Later
Play Later
Lists
Like
Liked1:19:32
Go online to PeerView.com/ZZW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in myelofibrosis discuss risk stratification, individualized care, and treatment strategies, including the use of JAK inhibitors and JAK inhibitor–based combinations. Upon completion of this accredited CE activity, participants should be better able to: Review modern risk stratification models, molecular features, cytogenetics, and clinical presentation of myelofibrosis, Evaluate the latest safety, efficacy, and tolerability data supporting the use of JAK inhibitors and other novel strategies, including JAK inhibitor–based combinations or sequencing approaches for managing transplant-eligible and transplant-ineligible patients with myelofibrosis, Address practical aspects of individualized care and risk-adapted therapy in myelofibrosis for managing lower- and higher-risk patients, including those failing prior JAK inhibitor therapy, Educate patients on the treatment strategies, what to expect when undergoing treatment with JAK inhibitor or JAK inhibitor–based combinations, and how they can effectively collaborate with the oncology team to monitor and manage therapy-related adverse events.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care 28:11
28:11
Play Later
Play Later
Lists
Like
Liked28:11
Go online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Appraise recent efficacy and safety data on newly available, guideline-based, and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Summarize ongoing/accruing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, for patients with advanced biliary cancers, Apply practice-changing clinical trial evidence to personalize the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential 27:59
27:59
Play Later
Play Later
Lists
Like
Liked27:59
Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach 58:09
58:09
Play Later
Play Later
Lists
Like
Liked58:09
Go online to PeerView.com/TWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psoriatic disease offer learners an in-depth look at the complex pathophysiology of psoriasis, current management paradigms, and challenges in the care of patients with moderate to severe disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Discuss the rationale for blocking the JAK-STAT pathway with small molecules as a treatment approach to psoriasis, Compare and contrast novel JAK inhibitors for the treatment of psoriasis in the context of selectivity, efficacy, and safety, Treat psoriasis in accordance with current evidence and guidelines, identifying patients with moderate to severe disease, who would likely derive benefit from novel nonbiologic oral therapeutic options.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients 29:58
29:58
Play Later
Play Later
Lists
Like
Liked29:58
Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.…
P
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

1 Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making… 46:22
46:22
Play Later
Play Later
Lists
Like
Liked46:22
Go online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the global disease burden, etiopathogenesis, risk factors, and stratification scores for cancer-associated VTE using established diagnostic tools, Review safety & efficacy evidence, clinical trial data, and practice guidelines for currently available treatment options for managing cancer-associated VTE, Employ guideline-concordant, evidence-based care and shared decision-making strategies including multidisciplinary and interprofessional collaboration for prevention and treatment of cancer-associated VTE in routine clinical practice.…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.